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1general inTroducTion and Thesis ouTline *
* Based on the book chapter “Groepsbehandeling voor zwangeren met ernstige psychiatrische klachten” 
in the “Handboek Psychiatrie en Zwangerschap” [1] 
Mental disorders are a major cause of disability among women during the perinatal period and 
may have consequences for her unborn child as well. A major depressive disorder (MDD) is 
the most common and known mental disorder during pregnancy, with prevalence rates varying 
between 3.1% and 11.0% [2]. Untreated or incompletely managed depression increases the 
risk of postpartum depression and maternal suicide, but may also impair fetal development, 
leading to a lower birth weight, premature birth and long term infant development [3]. Also 
other (co-morbid) mental disorders and psychosocial problems are important risk factors in 
the pathway of depression leading to adverse obstetric outcomes [4]. 
This introduction provides a comprehensive overview of symptoms, prevalence and specific 
issues of mental disorders during pregnancy, discusses the impact on a woman and her 
unborn child, and offers considerations for treatment. Treatment of antepartum mental 
disorders includes a variety of psychotherapeutic interventions and also pharmacotherapy, 
depending on the type and severity of the disorder, weighing potential risks for the woman 
and (unborn) child and individual preferences. Awareness, recognition and prompt referral are 
key to early intervention and prevention of long-term impairment of maternal well-being and 
adverse effect on the mother-child relationship and infant development.
A broad range of mental disorders and co-morbid disorders
This thesis applies to a heterogeneous group of pregnant women in different ways. First, it 
applies to a group of women whom are previously diagnosed with a mental disorder, or who 
otherwise have a history of psychiatric problems or treatment for a mental disorder. Pregnancy 
may potentially be a stressful period that can intensify symptoms, provoke exacerbations 
or give rise to associated disorders. But it also includes a group of pregnant women who 
experience psychiatric symptoms for the first time in their life.
Secondly, the heterogeneity of patients is also reflected by the broad range of mental 
disorders that are prevalent during pregnancy. The prevalence of all different mental disorders 
in pregnant women does not differ from outside of pregnancy. A large National Epidemiologic 
Survey performed among 43.094 women in the USA, showed no significant differences in the 
12-month prevalence of mental disorders between past-year pregnant women (25.3% fulfilled 
the DSM-IV criteria, using a structured diagnostic interview “SCID” [5]), postpartum women 
(27.5%), and non-pregnant women of childbearing age (30.1%). Except for the significantly 
higher prevalence of major depressive disorder (MDD) in postpartum women (9.3%) than in 
non-pregnant women (8.1%) (OR=1.59, 95% CI=1.15–2.20) [6]. In other words, pregnancy 
seems to be neither protective nor exacerbating [7, 8]. 
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Thirdly, in clinical obstetrical practice prevalence of mental disorders during pregnancy seems 
to be similar to cohort studies but showed a high number of co-morbid mental disorders in 
clinical studies. At an obstetric outpatient clinic, two studies showed that 24.0% had ≥2 or 
more co-morbid disorders and 5.0% had ≥3 or more co-morbid mental disorders [9, 10]. 
Most frequent axis 1 disorders were: anxiety disorders (21.7%, including specific phobia and 
panic disorder), MDD (8.8%) and eating disorders (0.9%). To our knowledge, only one study 
focused on the prevalence of personality disorders during pregnancy, which turned out to be 
6% based on a self-report measure [11].
Strikingly, most literature describing mental disorders during the antepartum period is available 
on MDD. Studies on other mental disorders during pregnancy are far less substantial. 
Emerging evidence suggests that comorbidity and psychosocial problems, including low socio-
economic status are important risk factors in the pathway of depression leading to adverse 
obstetric outcomes [4]. We subscribe the importance of recognizing the heterogeneous group 
of pregnant women with co-morbid psychiatric and psychosocial problems who are not eligible 
for routine treatments mainly focusing on depression. The following mental disorders have 
specific pregnancy-related characteristics in terms of prevalence, manifestation, or treatment 
and are described in table 1. 
During pregnancy, symptoms of a mental disorder like changes in mood, sleep, appetite and 
energy are often difficult to distinguish from the normal experiences of pregnancy. Although 
up to 70% of women report some negative mood symptoms during pregnancy, it is of key 
importance to check whether women meet diagnostic criteria according DSM-V [12]. The 
course of mental disorders during pregnancy varies: most studies report a peak of depressive 
symptoms during the first and second trimester and show improvement during the third 
trimester, in contrast to anxiety related symptoms which increase as the delivery approaches 
[13]. There is little information on specific phenotypes of mood disturbances in pregnant 
women with a mental disorder. 
Mood disturbances can cause sleeping problems; on the other hand sleep disturbances are 
also a symptom in several mental disorders. Approximately one-third of all pregnant women 
report sleeping problems and the persistence of disturbed sleep is associated with less 
mental well-being and adverse obstetric outcomes [14]. The underlying causal pathway is 
unknown, whether sleep quality in pregnant women is objectively worse in a sense of reduced 
or fragmented sleep, or whether their perception of it is altered, possibly as a result of co-
occurring psychiatric symptoms. 
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1Impact on mother and child Pregnant women with severe mental health problems need special care and attention. 
Untreated severe psychiatric symptoms have a major impact on the woman and on her 
partner/family. Unfortunately studies focusing on depression showed also adverse outcomes 
on pregnancy, delivery and the future child [3]. Direct influences of maternal stress in utero 
associated with depression may impair fetal development [20], leading to a lower birth weight 
[3], premature birth [21] and long term infants’ neurodevelopment [13, 22]. Exposure to 
elevated intrauterine cortisol levels makes the hypothalamus-pituitary-adrenal (HPA) axis of 
the child already susceptible to programming during fetal life, which place children at risk 
for developing psychopathology and other developing problems in later life. Although the 
fetal programming hypothesis is the most widely investigated possible explanation of the 
association between maternal psychopathology and child outcomes, there are more theories 
on this mechanism.
There are also indirect negative effects of having a mental disorder during pregnancy [23]. 
Pregnant women with a severe mental disorder have a worse self-care, avoid frequent prenatal 
checks, smoke more often and use more alcohol and drugs [24]. These indirect effects are not 
only harmful to the fetus, but also for the later child development. It becomes increasingly clear 
from research that early fetal development determines future adult health [25]. This applies 
to both ‘good’ (protective factors) as poor health outcomes. From a clinical perspective, it 
would be interesting whether fluctuations in mood - as often observed in pregnant women with 
and without mental disorder - affect child development or maternal mood in the postpartum 
period. Mood fluctuations have received more attention in the postpartum period because of 
the phenomenon of the ‘postpartum blues’ and its association with postpartum depression. 
Women suffering from a mental disorders during pregnancy are at an increased risks of 
postpartum depression [26] and maternal suicide [27].
In 2001 in the UK, the Confidential Enquiries into Maternal Death (CEMD) made us aware of 
the impact of mental illness on maternal deaths and identified suicide as the leading cause of 
late maternal deaths. Recent studies highlight a history of deliberate self-harm in a significant 
proportion (25 - 50%) of maternal suicides [28]. Compared with the postnatal period, women 
who die from suicide during pregnancy are more likely to have a diagnosis of schizophrenia 
related disorders or bipolar disorder and less likely to have a diagnosis of depression [29]. 
Little is known about the prevalence and risk factors of self-harm in pregnant women with a 
mental disorder, even though deliberate self-harm in pregnancy is potentially harmful to the 
viability of the pregnancy, in addition to being a potential risk factor for suicide. 
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Weighing risks and benefits for treatment 
The challenge for the treatment of a mental disorder during pregnancy is to offer the best 
and most effective treatment for the mother, with the least harm for the unborn child. 
Antidepressants are known to be effective in non-pregnant depressed women [30] and showed 
comparable effects to psychotherapy for depressive and anxiety disorders in non-pregnant 
women [31]. The disadvantage of pharmacotherapy are the side-effects for the mother and 
the largely - unknown - effects on the fetus. Many women as well as clinicians prefer not to 
start or continue the use of antidepressants during pregnancy [32], as long term effects of 
most pharmacotherapy on the fetal development are insufficiently known [33, 34]. Selective 
serotonin reuptake inhibitors (SSRIs) are the most frequently used pharmacotherapy in 
pregnant women with MDD, with an estimated 2-3% of women in Europe. The possible role 
of SSRIs in the prevention of relapse is also controversial [35, 36]. A recent study found that 
failure to use or discontinue antidepressants in pregnancy did not have a strong effect on 
the development of a major depressive episode [37]. Another study found that women who 
discontinue medication were more likely to relapse than women who continued medication 
(68 vs. 26%) [38]. The NICE guidelines from the UK advise clinicians to do a risk-benefit 
analysis, to weigh the risk of relapse against the potential risk for the fetus and encourage the 
use of non-pharmacological interventions [39]. Also in non-pregnant patients. 
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1Aims of this thesisAll overall aim of the present thesis is to extend existing knowledge on the treatment and 
impact of a mental disorder during pregnancy. This is of paramount importance, because of the 
lack of evidence-based treatment algorithms due to the complicated risk-benefit analysis for 
both mother and her unborn child, with a special focus on non-pharmacological interventions. 
Therefore, we will first systematically review all pharmacological and non-pharmacological 
interventions to treat antepartum mental disorders. Secondly, this dissertation evaluates the 
effectiveness of a new group-based multicomponent treatment for pregnant women with a 
mental disorder. At last, it explores the impact of a mental disorder during pregnancy on sleep 
and mood fluctuations and on suicidal ideation and self-harm. 
The aims of the thesis can be summarized as follows: 
1. To review all pharmacological and non-pharmacological interventions to treat mental 
disorders during pregnancy
2. To evaluate the efficacy of a new group-based multicomponent therapy in pregnant women 
with a mental disorder
3. To assess the impact of psychopathology on sleep quality by measuring the objective and 
subjective sleep quality of pregnant women with a mental disorder
4. To describe phenotypes of mood fluctuations across pregnancy and associations with 
pregnancy outcomes and postpartum depression
5. To investigate the prevalence of suicidal ideation and deliberate self-harm in pregnant 
women with a severe mental disorder
Setting
All studies included in this thesis were embedded in the DAPPER-trial, except for the study on 
suicidal ideation and self-harm. DAPPER is an acronym for Daycare Alternative Psychiatric 
Pregnant women Efficiency Research. It is a randomized controlled trial (RCT) to evaluate a 
new group-based multicomponent therapy to reduce depressive symptoms in pregnant women 
with a mental disorder. Pregnant women were recruited between January 2010 and January 
2013 after a diagnostic procedure at the tertiary outpatient clinic for perinatal psychiatry of the 
Department of Psychiatry, Erasmus University Medical Center (Erasmus MC), Rotterdam, the 
Netherlands. Rotterdam is the second largest city of the Netherlands and is characterized by 
a multi-ethnic population and large socioeconomically deprived neighbourhoods, with 10% 
of pregnant women having a low socio-economic status (<20th percentile). This is associated 
with adverse birth outcomes [40, 41], for example with 8000 newborns per year 10% being 
small of gestational age (<10th percentile) [42]. 
Patients were referred by general practitioners, midwives, gynaecologists and psychiatrists 
from the bigger area of Rotterdam-Rijnmond. Inclusion criteria were: a) mental and/or 
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personality disorder verified with the Structured Clinical Interview for DSM-IV-TR Disorders 
(SCID) [5] by a trained medical doctor; b) gestational age between 12 and 33 weeks; and 
c) written informed consent. Exclusion criteria were: a) indication for hospital admission; b) 
inability to function in a group due to severe behavioural problems e.g. aggression, suicidal 
behaviour, uncontrollable addictive behaviour; c) insufficient command of the Dutch language; 
or d) inability to visit the outpatient clinic. 
A group-based multicomponent treatment for pregnant women 
A decade ago at the Erasmus MC, in analogy with other evidence-based group treatments 
for mood- and personality disorders in non-pregnant patients, a group-based multicomponent 
therapy (GMT) for pregnant women with a mental disorder was founded. GMT aims to 
reduce stress, depressive and anxiety symptoms in women with co-morbid psychiatric 
and psychosocial problems with a special focus on emotional and practical preparation for 
motherhood. Pregnant women experience a stigma on having negative feelings towards their 
pregnancy and their unborn child. One of the major benefits of a group-based treatment is peer 
support; sharing problems and solutions, and reassurance by fellow patients. The medical 
team places the focus on reducing current psychiatric symptoms, strengthening coping 
strategies and increasing psycho-hygiene measures, such as avoiding stressful situations 
and giving practical tips on pregnancy and future motherhood.
The treatment takes place every week, covers multiple therapies and is given to an open group 
of maximum eight pregnant women. Before participation of the weekly therapy, a patient has 
to meet certain conditions: a diagnosed mental disorder, ≥12 weeks of gestation, a treatment 
plan and signal plan (to recognize deterioration) is composed at the outpatient clinic. Safety of 
the group has to be secured. In case a participant has severe suicidal or psychotic symptoms, 
she cannot participate. The program of the group-based multicomponent treatment includes:
- Weekly treatment evaluation and theme discussion: Led by a community psychiatric 
nurse (SPV) various topics related to pregnancy, the expectancy of motherhood and 
having a mental disorder are discussed. The goal of this therapy is that women 
learn how to deal with the challenging aspects of the upcoming motherhood and 
enhancing social support. 
- Psycho-education: A perinatal psychiatrist focusses on medical topics (incl. 
pharmacotherapy), recognizing and interpreting psychiatric symptoms and stimulating 
healthy behaviour. Experts from other disciplines are invited depending on the issues 
raised, for example an obstetrician, anesthesiologist or lactation expert.
- Cognitive Behavioural Therapy (CBT): A perinatal psychologist helps women to 
replace non-functional thoughts with more realistic thoughts (G-schemes) to reduce 
depressive and anxiety symptoms, and also helps strengthening coping strategies 
and problem-solving techniques.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General introduction and Thesis outline
17
1- Psychomotor therapy: An infant mental health-specialist encourages women to make contact with the unborn fetus and to actively learn how to relax. One of the goals is 
to increase maternal mentalization according to the applied-relaxation method of Ost 
(1987), stimulating bonding to the fetus and advises on maintaining a good sleep 
hygiene.
- Expressive and relaxation therapy by a creative arts therapist, who provides women 
several techniques and activities to find distraction and to reduce stress. 
Measures
Patients were referred to the outpatient clinic of the Erasmus MC. After an intake with a 
psychiatrist patients are contacted for study participation. After a structured diagnostic 
interview (“SCID” [5]) and fulfilling inclusion criteria written informed consent was obtained. 
Participants of the DAPPER-trial fulfilled 3 questionnaires to assess their sleep quality and 
depressive symptoms every 5 weeks during treatment until delivery. Participants were asked 
to fill in a weekly diary to assess their mood, sleep quality and to evaluate the offered treatment. 
Obstetric records of all mothers were looked up in the hospitals and supplemented as required 
at the 6 weeks postpartum home visit. 
 
 
 
 
      
SCID I & II
EDS
HDRS
EDS
HDRS
EDS
HDRS
EDS  
HDRS
Obstetrical 
outcomes
EDS
HDRS
PSQI
Weekly diary pregnancy
Note: GA= gestational age, SCID = Structured Clinical Interview DSM-IV disorders, EDS = Edinburgh 
Depression Scale, HDRS = Hamilton Depression Rating Scale, PSQI = Pittsburg Sleep Quality Inventory. 
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ouTline of This Thesis
This thesis aims to extend existing knowledge on the treatment (Part I) and impact (Part II) 
of a mental disorder during pregnancy. Chapter 2 gives a systematic review of the literature 
on treatments for mental disorders in pregnant women and a meta-analysis is performed 
to estimate the treatment effect of the interventions on the psychiatric symptoms during 
pregnancy. Chapter 3 describes the DAPPER-trial, a RCT evaluating a new group-based 
multicomponent therapy for pregnant women to reduce depressive symptoms. Part II of 
this thesis focuses on the impact of a mental disorder on sleep, mood and suicidal ideation 
during pregnancy. Chapter 4 focuses on the impact of a mental disorder on sleep quality by 
comparing subjective and objective sleep quality in a case-control study. Chapter 5 explores 
patterns of mood fluctuations in pregnant women with a mental disorder and investigates 
associations with obstetric outcomes and postpartum depression. In Chapter 6, we describe 
the prevalence of suicidal ideation and deliberate self-harm events in pregnant women with a 
severe mental disorder in London. Implications of this thesis and recommendations for further 
research are discussed in Chapter 7. Finally, the results of this thesis are summarized in the 
appendices.
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aBsTracT 
Background: For women suffering from an antepartum mental disorder (AMD), there is lack 
of evidence-based treatment algorithms due to the complicated risk-benefit analysis for both 
mother and unborn child. We aimed to provide a comprehensive overview of pharmacological 
and non-pharmacological interventions to treat AMD and performed a meta-analysis of the 
estimated treatment effect on the psychiatric symptoms during pregnancy.
Methods: MedLine, PsycINFO and Embase databases were searched by two independent 
reviewers for clinical trials with a control condition on treatment of women with AMD, i.e. 
major depressive (MDD), anxiety, psychotic, eating, somatoform and personality disorders. 
We inventoried the effect of the treatment, i.e. decrease of psychiatric symptoms at the end of 
the treatment or postpartum. We adhered to the PRISMA-protocol. 
Findings: Twenty-nine trials were found involving 2779 patients. Trials studied patients with 
depressive disorders (k=28), and anxiety disorders (k=1). No pharmacological trials were 
detected. A form of psychotherapy, like Cognitive Behavioural Therapy (g=-0.61; 95%CI:-0.73 
to -0.49, I2=0%; k=7) or Interpersonal Psychotherapy (g=-0.67; 95%CI:-1.27 to -0.07; I2=79%; 
k=4), holds robust benefit for pregnant women with MDD. Body-oriented interventions (g=-
0.43; 95%CI:-0.61 to -0.25; I2=17%; k=7) and acupuncture (g=-0.43; 95%CI:-0.80 to -0.06; 
I2=0%; k=2) showed medium sized reduction of depressive symptoms. Bright light therapy 
(g=-0.59; 95%CI:-1.25 to 0.06; I2=0%; k=2), and food supplements (g=-0.51; 95%CI:-1.02 
to 0.01; I2=20%; k=3) did not show significant treatment effects. One study was found on 
Integrative Collaborative Care.
Conclusions: This meta-analysis found a robust moderate treatment effect of CBT for MDD 
during pregnancy, and to a lesser extent for IPT. As an alternative, positive results were found 
for body-oriented interventions and acupuncture. No evidence was found for bright light 
therapy and food supplements. Only non-pharmacological trials on women with MDD were 
found. Research on a wider range of AMD is needed. 
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inTroducTion 
Antepartum mental disorders (AMDs) are a major cause of disability among women during 
the perinatal period, and may have consequences for children’s (intra-uterine) growth and 
development [1, 2]. To date, most reviews and treatments for antepartum mental disorders 
focussed on depression [3, 4] while a broader range of mental disorders is prevalent during 
pregnancy and psychiatric symptoms may overlap. The heterogeneity of patients is reflected 
by estimates from the National Epidemiologic Survey among 43094 American women, 
showing that the 12-month prevalence of the full range of AMDs did not differ from outside of 
pregnancy [5], nor resulting in lower rates [6, 7]. According to DSM-IV criteria, most prevalent 
AMDs were major depressive disorder (MDD), anxiety disorder and psychotic disorder in 
pregnant women. Prevalence rates of a mental disorder during pregnancy was 25.3%; almost 
equivalent among postpartum women (27.5%) and non-pregnant women (30.1%) [5]. 
In a hospital setting, the prevalence of AMDs is similar to cohort studies and additionally 
a high number of co-morbid mental disorders is found [8-11], e.g. several studies showed 
that 24.0% had ≥2 or more co-morbid disorders and 5.0% had ≥3 or more co-morbid mental 
disorders. To clinicians, a pregnant woman can present with a range of psychiatric and somatic 
symptoms, which sometimes overlap with typical “pregnancy complaints”. For diagnostic and 
therapeutic purposes, it is important to verify whether a patient dysfunctions in all life domains 
and to determine the mental disorder(s) according to the DSM-IV criteria. For MDD, DSM-V 
criteria remained the same and our outcomes can be extrapolated to the current situation. 
In consultation with the patient, a tailored treatment should be promptly offered, because of 
the on-going adverse influence of AMDs on the gestation and the increased risk to harmful 
health behaviours of mother, e.g. smoking, substance use, poor nutrition and avoidance of 
obstetric care [12, 13]. It has been hypothesized that most relevant effects of AMDs on the 
foetus take place during mid-gestation and are associated with adverse obstetric outcomes, 
including preterm delivery, low birth weight, hypertension and preeclampsia [14-17]. To protect 
the foetus, it is necessary to weigh the potential benefit of treating the mother’s AMD with 
psychotropic medication against the adverse effects of not treating or relapsing of AMD. 
There are no suitable data available to guide evidence-based decisions on pharmacological 
treatment of AMD during pregnancy. Selective serotonin reuptake inhibitors (SSRIs) are 
the most frequently used pharmacological treatment in pregnant women with MDD, with 
an estimated 2–3% of women in Europe. There a no studies on (dis)continuation of SSRIs 
during pregnancy, only two naturalistic studies investigated the preventive effect of SSRI’s for 
MDD during pregnancy and the results are equivocal [18, 19]. It poses pregnant women and 
clinicians for a dilemma, what is best for foetus and mother? 
From a patient and clinician perspective, there is need to explore evidence for pharmacotherapy 
and also alternative non-pharmacological treatments for AMDs. In case of depressive 
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disorders, several alternative treatment algorithms in non-pregnant women are shown to 
be effective [20] and Dennis et al. systematically reviewed these interventions in antenatal 
depression [21-23]. The authors concluded that for antenatal depression the evidence is too 
inconclusive to make any recommendations for depression-specific acupuncture, maternal 
massage, bright light therapy, and omega-3 fatty acids [21]. Various treatments for depression 
during pregnancy have been systematically reviewed [24-34], however, it remains unclear 
which non-pharmacological treatment clinicians should offer to pregnant patients with (co-
morbid) mental disorders other than depression. 
For clinicians it is important to know all available alternative treatments, next to pharmacotherapy, 
that he/she can offer to a patient with AMD. Our systematic review aimed to provide an 
overview of randomized or open intervention trials with a control condition that evaluated 
pharmacological and all non-pharmacological interventions for AMD. Subsequently, the aim 
of our meta-analysis is to provide an estimation of the overall effect size of a decrease of 
psychiatric symptoms at the end of treatment or postpartum, for each categorized intervention 
per mental disorder.
maTerials and meThods 
Eligibility criteria
To be selected for inclusion for our review, a trial was required to meet the following criteria: 
1. Type of participants
We considered trials that studied pregnant women with a diagnosed mental disorder, with a 
focus on the following mental disorders and grouped in 7 categories: 1) depressive disorder 
(MDD, dysthymic disorder); 2) anxiety disorder, e.g. agoraphobia, obsessive-compulsive 
disorder, panic disorder, phobic disorder, stress disorder, posttraumatic stress disorder; 3) 
eating disorder, e.g. anorexia nervosa, binge-eating, bulimia nervosa; 4) adjustment disorder; 
5) somatoform disorder; 6) schizophrenia and other disorders with psychotics features, e.g. 
bipolar disorder, or 7) personality disorder. We decided to exclude addiction or any substance-
use related disorders, e.g. nicotine-addicts or heroin users. Studies focussing on a population 
with psychosocial risk factors but without a diagnosed mental disorder were excluded. A 
prerequisite was that the AMD was diagnosed by means of a (semi-structured) psychiatric 
interview during pregnancy, e.g. SCID, Mini International Neuropsychiatric Interview (MINI), 
Composite International Diagnostic Interview (CIDI), Clinical Interview Schedule-Revised 
(CIS-R) for ICD-10 criteria or Diagnostic Interview Schedule (DIS), and not using screening 
instruments. 
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2. Type of treatment 
We considered all available pharmacological treatments for AMD, including antidepressants, 
mood stabilizers, antipsychotics, anxiolytics/tranquilizers and neuroleptics. Also all non-
pharmacological interventions for the treatment of AMD were taken into account, including all 
psychological, body-oriented therapies or other alternative forms of treatment, or combination 
of these interventions. We included trials that evaluated interventions, which had the primary 
aim to treat the mental disorder present during pregnancy. Interventions with the focus to 
prevent – or to treat risk factors for – postpartum psychopathology were excluded. 
3. Type of outcome measures:
We included all trials that were performed during pregnancy and evaluated the effect of the 
intervention at the end of the treatment period or closest to delivery in the postpartum period. 
We inventoried the effect of the treatment on the mental disorder of the mother, i.e. decrease 
of psychiatric symptoms at the end of treatment or postpartum closest to the delivery. 
4. Types of trials:
We included all studies with a randomized-controlled (RCT) or open trial design and were 
published in a peer-reviewed journal. For reasons of validity and quality, we decided to focus 
only on trials with a control condition and excluded abstracts, case-series and case reports. 
No language, publication date or publication status restrictions were imposed. 
Search strategy, data abstraction and synthesis for systematic review
Trials were identified by searching electronic databases, scanning reference lists of articles 
and consultations with experts in the field. MedLine, PsychInfo and Embase were searched 
from their inception to June 2016 using combinations of the following terms: Pregnancy, 
Mental disorders, Treatment (see Fig 1 for details and flowchart). To identify other published 
or unpublished trials, Clinical Trial Databases were searched (clinicaltrial.gov, The ICTRP 
Search Portal). The last search was run on June 2th 2016. Two reviewers (LR and AK) 
independently screened all titles and abstracts, excluded protocols and reviews and 
assessed full-text articles for eligibility. Disagreement between reviewers was resolved by an 
independent psychiatrist (MLvdB). Results are reported according to the PRISMA-protocol 
[35], but there was no review protocol. We assessed inter-rater agreement by kappa statistic 
using GraphPad Software. A kappa value of 0.61-0.80 reflects substantial, and a kappa-value 
of 0.81-1.00 (almost) perfect agreement [36]. Details related to the design of the trial, the 
participants (mental disorder definition and sample size), the description of the treatment and 
control condition and the outcomes of the trial were extracted from the articles and reported 
in Table 1. Most trials used multiple outcomes measures and our interest was to include the 
outcome measure that operationalized the clinical psychiatric symptoms best, i.e. preference 
for the Edinburgh (Postnatal) Depression Scale (EDS) which is validated for the use of 
assessment of depressive symptoms during pregnancy [37]. Our preference was to use the 
outcome data from the Intention To Treat analysis (ITT), and otherwise data from the per 
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protocol analysis. In case the trial design, procedure or mental health outcomes were reported 
in an unusual or inconclusive format, the corresponding author of the trial was requested 
for additional information. Five corresponding authors were contacted and four authors gave 
the additional information. In situations when multiple articles were drawn from the same 
trial, the most complete dataset was reported in detail. In case of multiple interventions, both 
interventions were reviewed, but in case of multiple control conditions only the primary control 
condition was reported. Pilots or feasibility trials are only mentioned briefly. Subsequently, per 
subgroup of mental disorders (as described above) the studied interventions and their effect 
on the mental disorder at the end of therapy or trial, preferably the time point closest to the 
delivery is presented. 
Figure 1 - Flow diagram of the review selection procedure, adhered to the PRISMA statement
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Risk of bias in individual trials and across trials
The reviewers independently rated the risk of bias for each trial according to the Cochrane 
Risk of Bias Tool and reported randomization procedure, allocation concealment, blinding 
procedures and selective reporting in Appendices B [38, 39]. Publication bias was visually 
assessed with a funnel plot and formally with Egger’s test, to see if the effect decreased with 
increasing sample size [40]. These plots should be shaped like a funnel if no publication bias 
is present. However, since smaller or non-significant trials are less likely to be published, trials 
in the bottom left-hand corner of the plot are often omitted.
Procedure for meta-analysis
For our meta-analysis, we used the same search strategy as mentioned before and included 
only randomized controlled trial designs. We excluded open trials. We calculated pooled 
estimates using bias corrected standardized mean estimates, i.e. Hedges’ g, with 95% 
confidence intervals between the intervention group and the control group at the end of the 
trial or postpartum closest to the delivery. Hedges’ g corrects for the differences in variances 
resulting from the inclusion of trials with varying sample sizes [41]. The magnitude of Hedges’ 
g can be interpreted as small (0.20), moderate (0.50), or large (0.80) in line with Cohen’s d 
[42]. Pooling was performed per type of intervention and per category of mental disorder over 
a minimum of two trials. Results for each subgroup of intervention are plotted in a forest plot. 
Random-effects analysis were used to estimate an overall treatment effect since it produces 
a more reliable estimate than fixed effect analysis in case of substantial heterogeneity. 
Cochran’s Q-test, I2, and T2 statistics were used to quantify heterogeneity across trials. I2 
>40% was considered as substantial heterogeneity. Heterogeneity was further explored by 
conducting sensitivity analyses. For this aim, we calculated the overall treatment effect using 
both fixed and random effects modelling and evaluated the impact of the modelling procedure 
on the overall treatment effect [43]. Additionally, we created subgroups of trials based on 1) 
modus of intervention (group-based vs. individual therapy), 2) timing of outcome assessment 
(end of therapy vs. in the postpartum period), 3) randomization, i.e. secure vs. unknown, 4) 
allocation concealment (secure vs. unknown/insecure), 5) attrition (less vs. more than 20%), 
6) overall study quality (unbiased, unknown/partially biased vs. biased), and 7) outcome 
measure (questionnaire used), and we evaluated the impact of these moderator variables 
on the overall treatment effect. Finally, we assessed the influence of the age of the patient 
as a continuous variable on treatment effect using random effects meta-regression analysis. 
Standardized effect sizes were calculated using Comprehensive Meta-Analysis (CMA) [44]. 
Further statistical analyses were performed using the “Metan package” in Stata 13 [45, 46]. 
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resulTs 
Using our search strategy, we identified 7021 articles (see Fig 1 for a flow diagram). After 
reviewing the title and abstract, 63 articles were assessed for eligibility and 37 articles did 
not meet the inclusion criteria. We included 27 articles reporting a clinical trial with a control 
condition evaluating a treatment for AMD. After cross checking the references, we added 
2 relevant articles (A10, A18), thus we included 29 articles in our systematic review. Inter-
rater reliability was very good (raw inter-rater agreement= 94%; κ=0.87). All 29 articles were 
published in English between 1997 and 2015 (see Table 1 for a summary of all included 
articles). A reference list of all included articles is presented in Appendices A. Together the 
articles described 28 unique studies; Burns et al. (A2) and Pearson et al. (A21) published on 
the same study cohort. Collectively there were a total of 2779 participants in the trials. Almost 
all participants were diagnosed with a depressive disorder (k=28) and, to a lesser extent 
diagnosed with an anxiety disorder (k=1). No trials were detected with participants diagnosed 
with AMDs, psychotic disorder, eating disorder, somatoform disorder or personality disorders. 
Included trials described the effects of a variety of different interventions, e.g. Cognitive 
Behavioural Therapy (CBT), Inter Personal Therapy (IPT), bright light therapy, body-oriented 
interventions, acupuncture, food supplements and Integrative Collaborative Care (ICC). The 
treatment period ranged from 2 to 16 weeks and number of sessions varied between 2 to 
32 sessions. Assessment of outcome differed in timing, e.g. end of treatment period (k=25) 
or postpartum period (k=4), and type of questionnaire frequently used were EPDS (k=9), 
CES-D (k=7) and BDI (k=4). The majority of the trials randomly allocated participants to 
an intervention or control condition (k=27), except for two trials with an open design. In the 
following paragraphs, the results of the different interventions per diagnostic subgroup are 
described. 
Depressive disorder 
In general, the results from 28 unique trials focusing on the treatment of a depressive disorder in 
pregnant women indicated beneficial effects in relation to a decrease of depressive symptoms 
at the end of treatment or in the postpartum period. These trials included participants that 
fulfilled the criteria for MDD according to DSM-IV or ICD-10 criteria. Participants were 
diagnosed with the SCID (k=16), MINI (k=3), DIS (k=2), CIS-R (k=2) or other clinical (semi-
structured) psychiatric interview (k=5), often combined with a screening instrument. The 
majority of the studies were conducted in a Western country (Australia, Sweden, Switzerland, 
UK, USA) and three trials were conducted in a low-resource country (Pakistan, Korea and 
Taiwan). The majority of the sample sizes of the included trials were small, varying from 10 to 
903 participants and covered in total 2703 participants. Except for one open trial, all trials were 
(partly) randomized controlled trials. 
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In total, 8 trials evaluated CBT, 4 trials evaluated IPT, 3 trials examined the use of bright light 
therapy, 7 trials were on body-oriented therapies, 2 trials on acupuncture, 3 trials on food 
supplements and one trial on ICC. Participants were individually exposed to the intervention 
(k=21) or the treatment was delivered to a group (k=7). Reduction of depressive symptoms 
was expressed in scores on the EPDS (k=9), CES-D (k=7), BDI (k=4), HDRS (k=3), SIGH-
SAD (k=3), CIS-R (k=2), SCL-20 (k=1) at the end of treatment (k=23) or postpartum (k=3). 
Cognitive behavioural therapy (CBT) 
Austin et al. conducted one of the first large RCTs to demonstrate the superiority of CBT over 
a booklet and provided weekly 2-hour CBT group sessions for 6 weeks (A1). Per protocol 
analyses showed that both groups symptomatically improved over time but there was no 
difference between the two groups. Cho et al. conducted a pilot randomized controlled trial to 
compare CBT with psycho-education with twenty-seven depressed patients. The intervention 
group received 9 sessions of individual CBT and had significantly lower rates of depression 
one month after childbirth (A3). In a low-resource setting, Rahman et al. conducted a large 
cluster-randomized controlled trial and trained community health workers to provide a CBT-like 
intervention at home. Although the primary outcome was infant weight and height at 6 months 
postpartum, less mothers met criteria for major depression in the intervention group than in the 
control group (OR 0.22 95%CI: 0.14 to 0.36, p<0.001) (A22). Also in another setting, Hayden 
studied pregnant women with diabetes and with depression (n=34) and without depression 
(n=68), but CBT had no beneficial effect over supportive counseling for both groups (A14)\. 
More recent, Burns et al. and Pearson et al. investigated CBT in a pilot RCT and randomized 
36 British women who received up to 12 sessions of individual CBT (A2,A21). At 15 weeks 
post-randomization (linked to a gestational age of approx. 29 weeks), there were more women 
in the intervention group who did not met ICD-10 criteria for depression any more than in the 
control group (68.7% vs. 38.5%) and Pearson et al. suggested that the attentional biases of 
women might improve after CBT. In a pilot RCT, O’Mahen et al. showed that CBT is also a 
feasible and acceptable treatment for low-income, racial minority women with MDD, however 
depression scores did not significant differ between the intervention and treatment as usual 
group (A19). Milgrom et al. showed promising results of an adapted version of a postnatal CBT 
program, containing 8 antepartum sessions and also reports infant outcomes at 9 months, 
however post-treatment the depression scores were not significant better for the intervention 
group (A29). 
Interpersonal Psychotherapy (IPT)  
Spinelli and colleagues were the first to compare a 16-week IPT intervention with parent 
education matched in time and intensity (A24)[47]. The majority of women were low-income 
Spanish speaking immigrants, and patients who received IPT had a significant >50% 
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improvement in their mood symptoms. This trial was replicated in 2013 and showed equal 
benefits of both interventions (A25). Grote et al. reduced the number of sessions from 16 to 
8 (brief-IPT) and still a significant larger proportion (95%) of the women in the intervention 
group no longer met the criteria for MDD compared to the enhanced usual care (58%) at 
3 months postpartum (A13). Field et al. studied IPT in a group of women with dysthymia or 
major depression and after 12 sessions there was no difference in mood symptoms between 
the intervention and the control peer-support group (A6). 
Bright light therapy
Three trials have examined the use of bright light therapy for the treatment of antepartum 
depression. Oren et al. exposed 16 patients for 3 weeks to active bright light in an ABA-
design and SIGH-SAD scores improved by 49% from baseline (A20). Withdrawal of bright 
light treatment was associated with an increase of depressive symptoms. Epperson and 
colleagues found no significant benefit of bright light over placebo during a 5-week RCT (A4). 
However, in the extended 10-week trial, active bright light with 20,000 lux had a significant 
treatment effect compared to 500-lux dim light (effect size 0.43). Wirz-Justice et al. reported 
a significant difference on HDRS and SIGH-ADS (MD= -5.00, 95%CI:-10.00 to 0.00) scores 
comparing active (7000 lux) to placebo (70 lux) light therapy after 5 weeks of treatment (A28). 
Body-oriented interventions
Field et al. studied extensively alternative antepartum interventions for depression (A5-
A11). Massage by a significant other, compared to standard care significantly decreased the 
number of women with depressive symptomatology on the Center for Epidemiological Studies 
Depression Scale (CES-D) immediately post-treatment in a small (n=47, MD=-4.9) (A11) and 
bigger sample (n=149, MD=-6.7, 95%CI:-9.8 to -3.6) (A9). Field et al. studied also group-IPT 
in pregnant women and added 6 sessions of massage therapy for the intervention group (A5). 
The group that received both interventions, showed a greater decrease in depression and 
anxiety scores. Recently these authors compared yoga or massage therapy twice weekly 
(A10), tai chi/yoga therapy (A8) and weekly yoga to standard antepartum care for 12 weeks 
(A7). These three trials showed a significant greater decrease of depression and anxiety 
scores in the intervention groups compared to the control groups. Uebelacker compared group 
yoga with a mom-bay wellness workshop and found no difference in depression scores (A27).
Acupuncture 
Two trials examined the role of acupuncture, Manber and colleagues studied depression-
specific acupuncture in comparison with non-specific acupuncture and massage therapy 
(A16-A17). In a small sample in 2004, there were no differences in pregnant women diagnosed 
with clinical depression after treatment nor at 10 weeks postpartum (A16). A new sample of 
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150 patients in 2010 showed that women who received acupuncture specific for depression 
experienced a greater reduction of HDRS-rates, compared with the combined controls or 
control acupuncture after 8 weeks of treatment (A17).
Food supplements
Three trials have explored the potential value of food supplements. For example, Freeman 
performed a randomized double blind placebo controlled trial to compare the use of omega-3 
fatty acids to placebo, with supportive psychotherapy provided to all patients (A12) and studied 
therapy adherence [48]. Both groups experienced a significant improvement in self-reported 
and observer rated depression over 8 weeks, although there were no group differences. In 
contrast, Rees et al. published a negative but properly executed trial on the use of omega-3 
fatty acids in a double blind, placebo-controlled trial (A23). Su et al. concluded the superiority 
of omega-3 fatty acids and showed that the intervention group had significantly lower mean 
HDRS scores (MD=-4.70, 95%CI:-7.82 to -1.58) after 8 weeks of treatment (A26). At the trial 
endpoint, patients in the omega-3 group also had lower depressive symptom ratings on the 
EPDS and BDI. 
Integrative collaborative care (ICC)
Multidisciplinary care and personalized care have received a lot of attention. Melville et al. 
evaluated their ICC in a RCT at an obstetric outpatient clinic which included an engagement 
session, an assessment by a Depression Care manager and potentially supported by 
antidepressant medication or problem-solving therapy for primary care for 1 to 4 weeks 
(A18). After one year, the intervention group had significant greater decrease of depressive 
symptoms on the Hopkins Symptom Checklist-20 compared to the usual care group. 
Anxiety disorders 
Only one trial fulfilled the inclusion criteria for the treatment of anxiety disorders in pregnant 
women. This trial included patients that met criteria for anxiety disorder or blood- and injection 
phobia according to DSM-IV criteria. The sample size of the included trial was 76 patients and 
evaluated CBT in an open trial (A15). Patients received two sessions of group-CBT and were 
compared with 46 women diagnosed with blood- and injection phobia, but untreated. CBT-
treated women scored significantly lower after each session and postpartum on anxiety and 
avoidance scores. 
Methodological quality of trials and risk of bias
Data available for the meta-analysis was provided by 25 trials and methodological quality was 
reported in a risk of bias table in Appendices B. Twelve trials did not describe the procedure 
of concealment of allocation and randomization. Blinding of the participants was not always 
feasible, but in twelve trials participants or assessors were blinded. Attrition rates varied from 
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0 to 52%. Majority (72%) of the trials did not publish a protocol and/or was registered in a trial 
register. Inter-rater agreement with regards to the quality assessment was substantial (raw 
inter-rater agreement= 83%; κ=0.70).
A visual inspection of the funnel plot revealed that the plot was symmetric, so we had no 
indication of a publication bias (see Fig 3). Only three studies were identified outside the 
pseudo 95% confidence interval (A10,A12,A24). Also, the Egger’s test did not suggest the 
presence of publication bias (β=0.08; 95%CI:-0.83 to 0.99; p=0.86). 
Figure 3 - Hedges g of interventions to reduce depressive symptoms in pregnant women.
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Meta-analysis
For the patients with depression, we grouped the available interventions together in 1) 
CBT; 2) IPT; 3) bright light therapy; 4) body-oriented therapies; 5) acupuncture; and 6) food 
supplements (see Fig 2). No overall statistics were calculated for Integrating Collaborative 
Care (k=1) and a trial focussing on patients diagnosed with an anxiety disorder (k=1). For 
each intervention subgroup, we compared all available trials on improvement of psychiatric 
symptoms and study quality as reported in S1 Table. Analysed in a random effect model, 
the psycho-therapeutically interventions were both associated with reduction of depressive 
symptoms. In case of CBT, treatment size was medium with little inconsistency between 
trials (g=-0.61; 95%CI:-0.73 to -0.49), and overall effect was significant (Z-value=10.04; 
p<0.001). Among the 7 trials evaluating CBT, there was no evidence of heterogeneity 
(Tau2<0.001; Chi2(6)= 2.72; p=0.84; I2<1%). In case of IPT the effect was also medium. 
However, the magnitude of the imprecision shows large inconsistencies between the trials 
(g=-0.67; 95%CI:-1.27 to -0.07). Inconsistency among the four IPT trials was supported by 
the test for heterogeneity (Tau2=0.29; Chi2(3)= 14.01; p<0.001; I2=79%). Overall the treatment 
effect of IPT was significant (Z-value=2.20; p=0.03). Overall treatment effect of bright light 
interventions was not associated with a decrease of depressive symptoms (g=-0.59; 95%CI:-
1.25 to 0.06; I2=0%; Z-value=0.77; p=0.08). Heterogeneity was not tested significantly 
(Tau2<0.001; Chi2(1)= .83; p=0.36; I2<1%). Body-oriented intervention was associated with 
a medium sized improvement, consistent over the trials (g=-0.43; 95%CI:-0.61 to -0.25), 
overall treatment effect was significant (Z-value=4.62; p<0.001). Heterogeneity was not tested 
significantly (Tau2=0.02; Chi2(7)= 8.41; p=0.30; I2=17%). Treatment with food supplements 
was not associated with decrease of depressive symptoms (g=-0.51; 95%CI:-1.02 to -0.01; 
Z-value=1.92; p=0.06). Heterogeneity was not tested significantly (Tau2=0.04; Chi2(2)= 2.49; 
p=0.29; I2=20%). Finally, the two trials evaluating acupuncture showed a significant medium 
overall treatment effect (g=-0.43; 95%CI:- 0.80 to 0.07; Z-value=2.30; p=0.02). Heterogeneity 
was not tested significantly (Tau2<0.001; Chi2(1)= 0.03; p=0.86; I2<1%). 
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Figure 2 - Funnel plot including pseudo 95% confidence limits of the included trials (k=25) stratified by 
intervention.
Sensitivity analysis
Fig 4 depicts the results from the sensitivity analyses. As the figure shows, the overall treatment 
effect regarding symptoms of depression is robust to intervention and trial characteristics 
and statistical method. The mode of intervention, i.e. group vs. individual therapy, nor any 
of the trial design characteristics, i.e. outcome measure, moment of assessment, nor any of 
the trial quality characteristics showed a significant impact on the overall intervention effect. 
Regression analysis revealed no significant association between treatment effect and the age 
of the included patients (β =0.01; 95% CI:-0.03 to 0.06, p=0.69).
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Figure 4 - Intervention effect in the full set of included trials (k=25) using fixed and random estimation, and 
for different subgroups of trials. Pooled effect sizes for subgroups of trials are estimated using random-
effects estimation. Fixed-effect estimation was used to compare differences over subgroups.
discussion 
Summary of evidence
The aim of this systematic review was to provide an overview of trials that evaluated 
pharmacological and non-pharmacological interventions for AMD and in addition to provide 
an estimation of the overall effect size of categorized interventions per mental health outcome. 
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Given the importance of treating mental disorders during pregnancy for mother and child, 
this meta-analysis extends the literature [29, 33, 34, 49] by thoroughly examine all available 
treatments for AMD. 
Until this date there are no controlled studies on the effect of psychotropic medication for 
AMD. We could only estimate effect sizes for treatment of patients diagnosed with Major 
Depressive Disorder (MDD) by a lack of studies on other mental disorders during pregnancy. 
A form of psychotherapy for MDD has robust effect sizes, e.g. Cognitive Behavioural Therapy 
(CBT, g=-0.61), and to a lesser extent Interpersonal Psychotherapy (IPT, g=-0.67). Both may 
hold potential benefit for pregnant women with MDD in this analysis. This is in line with current 
NICE guideline that advises clinicians to offer a form of psychotherapy to every pregnant 
woman with a history of mild to severe depression and emphasizes close consultation with 
patients [50]. 
Other potential beneficial non-pharmacological intervention categories to treat MDD were 
body-oriented interventions and acupuncture. Our data suggests that bright light therapy 
is not associated with a decrease of depressive symptoms, but this is based on two trials. 
Overall, we identified only a small number of studies for each intervention category with small 
sample sizes and potential risks of bias. We performed sensitivity analyses to evaluate the 
impact of these moderator variables on the overall treatment effect, but none showed to be 
significant. However, the ability to perform certain moderation analyses was limited by the size 
and quality of current English literature. In the majority of the trials only per protocol data was 
available and this has likely resulted in an overestimation of our effect sizes. 
Our results showed that the overall effect sizes of all non-pharmacological intervention are 
in close range to each other and may be redeemable for one other, bearing in mind the high 
attrition rates of most trials. Furthermore, the effect sizes are similar or even higher than the 
effect of psychotropic medication in non-pregnant depressed patients [51-53]. In summary, 
the effect sizes of the different interventions to treat depressive symptoms are close to each 
other and therefore we suggest that the preference of the patient have to weigh heavily in the 
decision for a psychiatric treatment in a clinical setting. 
Strengths and limitations
To our knowledge, a broad approach to examine various interventions for mental disorders 
during pregnancy is not performed before. We limited our study to a clinical group of patients with 
a diagnosed disorder, in order to extrapolate the evidence on treatment of AMDs for clinicians. 
The disadvantage of this approach is that we missed potentially effective interventions in a 
healthy population that could be beneficial also for a clinical sample. By pooling the interventions 
by six subgroups in our meta-analysis and conducting several sensitivity analyses, we believe 
that we have been able to show the effects of each intervention and gained insight in sources 
of variability between the included studies. Our estimates are lower than other meta-analysis 
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which report average effect for IPT, ranging between 1.14 (one-group studies) [33] to 1.26 
[29]. We focused only on the treatment period during pregnancy, on a clinical diagnosis and 
controlled trials, therefore our results show a more robust estimate of the beneficial effect 
of IPT for pregnant women with MDD. Post-hoc analysis of Claridge et al. focusing on high 
quality clinical samples, found similar effect sizes (d=0.40) [33]. 
We considered also open trials in our qualitative systematic review, because it is known that 
this hard-to-reach population is difficult to enrol and randomize for trials, due to practical and 
ethical reasons. As indicated by the funnel plot and Egger test, there was likely no publication 
bias in this synthesis, and also our sensitivity analysis showed no potential biases. Altogether, 
the advantage of our broad and systematic approach resulted in a comprehensive overview 
and robust results. 
Implications and conclusions
This meta-analysis contributes to the literature in several ways. Our review shows that the 
number of trials on treatment of AMD is low, although rising every year. No controlled studies 
were found to show evidence for the use of psychotropic medication during pregnancy. We 
highlight the continuing need for further research of antepartum treatment for the full spectrum 
of AMDs, e.g. anxiety disorders, psychotic disorders, eating disorders, psychosomatic 
disorder and comorbidity like personality disorders. The evidence provided is inconclusive, 
and is predominantly based on trials evaluating major depressive disorder during pregnancy 
in small sample sizes. It is recommended that future research include other mental disorders 
in larger numbers and study alternative non-pharmacological interventions in comparison with 
pharmacotherapy. Findings of alternative interventions offer the promise of efficacy without the 
complexity of weighing pros and cons regarding foetal exposure to psychotropic medication 
and maternal stress. For example body-oriented therapies (g=-0.43) and acupuncture (g=-
0.43) are promising alternatives, but the evidence is based on two to four trials and the 
results should be replicated, preferably by researchers from different institutes. The results 
of omega-3 fatty acids intake are mixed and also a recent meta-analysis in non-pregnant 
depressed patients suggests a small, non-significant benefit. However, nearly all of the 
treatment efficacy might be attributable to publication bias [54]. Bright light therapy showed to 
be effective for the treatment of non-seasonal depression in non-pregnant population [55], but 
needs further research in pregnant women. 
Our systematic review found also a high number of protocols, which are promising as well. 
For example protocols for tapering antidepressants during pregnancy [56], for a broader 
range of mood disorders [57-59] and a rise of mindfulness-based therapies is observed [60]. 
Due to the small number of participants or weaknesses in design of the studies, we could 
not include other alternative interventions that showed promising effect in case-series, e.g. 
Electroconvulsive Therapy [61] and Transcranial Magnetic Stimulation [62, 63], or in healthy 
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pregnant women, e.g. exercise [64], music therapy [65] or multicomponent psychotherapy 
[66]. For future research it would be interesting to examine the association between the 
severity of the disorder with the improvement of psychiatric symptoms to further personalize 
treatments. It should also be noted that the evidence was identified for short-term outcomes of 
AMD, and that further research is needed to evaluate longer-term mother and child outcomes. 
To conclude, in the field of perinatal psychiatry there is a lot of attention for depression and 
a couple of evidence-based therapies are available and redeemable. However, the broader 
range of mental disorder are not represented in current literature, while anxiety, bipolar and 
other psychotic disorders may adversely affect mother and foetus, we strongly recommend 
further research on both pharmacological and non-pharmacological treatment options for all 
mental disorders during pregnancy.
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aBsTracT
Background: Depressive symptoms in pregnant women, which are common and debilitating, 
are often co-morbid with other mental disorders (e.g. anxiety and personality disorders), and 
related to low socioeconomic status (SES). This situation may hamper treatment outcome, 
which has often been neglected in previous studies on the treatment of depression during 
pregnancy. We developed a new group-based multicomponent treatment (GMT) comprising 
cognitive behavioral therapy, psycho-education and body-oriented therapy and compared 
the effect on depressive symptoms with individual counseling (treatment as usual, TAU) in a 
heterogeneous group of pregnant women with co-morbid mental disorders and/or low SES. 
Methods: An outpatient sample from a university hospital of 158 pregnant women who met 
DSM-IV criteria for mental disorders were included and 99 participants were randomized to 
GMT or TAU from January 2010 until January 2013. The Edinburgh Depression Scale (EDS) 
was used at baseline, every 5 weeks during pregnancy and as the primary outcome measure 
of depressive symptoms at 6 weeks postpartum. Secondary outcome measures included 
the clinician-reported Hamilton Depression Rating Scale (HDRS), obstetric outcomes and a 
‘Patient Satisfaction’ questionnaire.  
Results: 155 participants were included the intention-to-treat (ITT)-analysis. GMT was not 
superior above TAU according to estimated EDS (β=0.13, CI=-0.46 – 0.71, p=0.67) and HDRS 
scores (β=-0.39, CI=-0.82 – 0.05, p=0.08) at 6 weeks postpartum. There were no differences 
in secondary outcomes between the GMT and TAU, nor between the randomized condition 
and patient-preference condition. Limitations: The ability to detect an effect of GMT may have 
been limited by sample size, missing data and the ceiling effect of TAU.   
Conclusions: GMT is an acceptable treatment for a heterogeneous group of pregnant women 
with depressive symptoms and co-morbid mental disorders and/or low SES, but not superior 
to TAU. Further research should focus on understanding and treating co-morbid disorders and 
psychosocial problems during pregnancy. 
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inTroducTion
Depression during pregnancy is common, with prevalence rates varying between 3.1% and 
11.0% in the general population [1]. Fortunately, there is growing awareness of the risks of 
untreated prenatal depression for both mother and her unborn child [2, 3]. For example, 
untreated or incompletely managed depressive symptoms increase the risk of postpartum 
depression [4] and maternal suicide [5]. Also, indirect influences of prenatal depression (e.g. 
reduced self-care, more smoking and substance use) [6],[7] and direct influences of maternal 
stress in utero associated with depression may impair fetal development [8], leading to a 
lower birth weight [9], premature birth [10] and long term infants’ neurodevelopment [11, 12]. 
The growing awareness of the negative impact of maternal depression on maternal and child 
outcomes has led to the development of various psychosocial and psychological therapies 
to treat depression during pregnancy [13, 14]. Because of unknown risks of psychotropic 
medication for the unborn child [15], clinicians and patients express a preference for non-
pharmacological interventions [16]. There are several studies that investigated the effects of 
psychotherapy on depression during pregnancy [17-19]. For example, Cognitive Behavioral 
Therapy [20-23], Interpersonal Psychotherapy [24, 25] and mindfulness-based cognitive 
therapy [26] showed small to moderate effect sizes in pregnant women [18]. Various 
psychosocial and multimodal interventions have been carried out during pregnancy to reduce 
depressive symptomology, however the evidence is inconclusive [27-29]. The majority of 
these studies targeted women with sub-clinical symptomatology, or had the primary aim to 
prevent postpartum depression, for example in antenatal classes [30, 31].  
However, next to depression, other psychiatric disorders may co-exist during pregnancy 
[32-34]; 5.0% to 24.0% of patients in a clinical setting have two or more diagnosed co-
morbid psychiatric disorders [35-37], with a high incidence of anxiety-related disorders. To 
our knowledge, only one study focused on the prevalence of personality disorders during 
pregnancy, which turned out to be 6% based on a self-report measure [38]. Emerging 
evidence suggests that comorbidity and psychosocial problems, including low socioeconomic 
status (SES) are important risk factors in the pathway of depression leading to adverse 
obstetric outcomes [39]. Also, women with pre-existing psychiatric vulnerability might relapse 
during pregnancy [38], for example due to unplanned pregnancy or inadequate social support 
or unhealthy life style. Moreover, treatment of pregnant women with psychiatric disorders 
puts extra challenge in a limited period of time because of lower rates of engagement and 
compliance, comorbidity, stigma and other barriers to seek treatment [40-43]. Women in 
large urban areas might be more at risk due to clustering of a multi-ethnic population and 
large socioeconomically deprived neighbourhoods, which is associated with adverse birth 
outcomes [44, 45]. As a consequence, in clinical practice, psychiatrists are often faced with a 
heterogeneous group of pregnant women with psychiatric co-morbidity and low SES who are 
not eligible for routine treatments mainly focusing on depression. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 3
58
Based on longstanding clinical experience and relying on evidence-based components 
from other treatments during pregnancy [19], we composed a Group-based Multicomponent 
Treatment (GMT) that aims to reduce stress, depressive and anxiety symptoms in women 
with co-morbid psychiatric and psychosocial problems with a special focus on emotional and 
practical preparation for motherhood. This weekly one-day treatment is provided in an open 
group, as positively viewed by women in a recent Cochrane review [46], to encourage peer-
support and decrease social isolation and stigma. The treatment consisted of the following 
5 consecutive components, based on our longstanding clinical experience and the existing 
evidence to treat mental disorders during pregnancy [19, 47]: 1) weekly evaluation of 
treatment goals by a social psychiatric nurse; 2) psycho-education by a perinatal psychiatrist; 
3) cognitive behavioral therapy (CBT) by a clinical psychologist; 4) body-oriented therapy 
by an Infant Mental Health specialist, and 5) relaxation therapy by a creative arts therapist. 
Treatment as usual (TAU) comprised low frequent, individual counseling sessions provided by 
a social psychiatric nurse or a medical doctor. Both treatments were provided at the outpatient 
clinic and the number of sessions was based on an assessment of the patient’s needs. 
We hypothesized that Group-based Multicomponent Treatment (GMT) would be more effective 
than treatment as usual (TAU) in reducing depressive symptoms in women with co-morbid 
psychiatric and psychosocial problems. Because of known low recruitment and engagement 
rates in this hard-to-reach population [42], we introduced a patient-preference condition, for 
women not willing to randomize, to additionally investigate the effect of patients’ preference 
for a group-based or individual therapy on treatment response [48]. This patient-preference 
randomized controlled trial enabled us to compare the effectiveness of our GMT vs. TAU and 
randomized vs. patient-preference conditions, in terms of reduction of depressive symptoms, 
obstetric outcomes, feasibility and patient’s satisfaction on the treatment.
meThods
Study design and procedure
The study design was a single center patient-preference randomized controlled trial, 
comparing Group-based Multicomponent Treatment (GMT) versus individual counseling 
(treatment as usual, TAU). Eligible participants were randomized to GMT and TAU condition 
(1-to-1), stratified for gestational age less <24 weeks or more than ≥24 weeks). Participants 
who rejected randomization were invited to participate in parallel non-randomized patient-
preference treatment conditions. Participants in the patient-preference treatment conditions 
underwent the same procedures as the randomized patients. This design provided four 
arms: a) randomized GMT; b) randomized TAU; c) patient-preference GMT and d) patient-
preference TAU. We compared treatment effect of GMT versus TAU, and randomized versus 
patient-preference conditions. 
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Participants
Pregnant women were recruited between January 2010 and January 2013 after a diagnostic 
procedure at the tertiary outpatient clinic for perinatal psychiatry of the Department of 
Psychiatry, Erasmus University Medical Center (Erasmus MC), Rotterdam, the Netherlands. 
Rotterdam is the second largest city of the Netherlands and is characterized by a multi-ethnic 
population and large socioeconomically deprived neighborhoods. Patients were referred 
by general practitioners, midwives, gynecologists and psychiatrists from the bigger area 
of Rotterdam-Rijnmond. Inclusion criteria were: a) psychiatric and/or personality disorder 
verified with the Structured Clinical Interview for DSM-IV-TR Disorders (SCID) [49] by a 
trained medical doctor; b) gestational age between 12 and 33 weeks; and c) written informed 
consent. Exclusion criteria were: a) indication for hospital admission; b) inability to function in 
a group due to severe behavioral problems e.g. aggression, suicidal behavior, uncontrollable 
addictive behavior; c) insufficient command of the Dutch language; or d) inability to visit the 
outpatient clinic. Ethical approval was obtained from the hospital’s Medical Ethics Committee 
of the Erasmus Medical Center. The trial was registered in the Dutch Trial Registry (www.
trialregister.nl, number NTR3015).
Group-based multicomponent treatment 
We composed a weekly, all-day (6 hours) therapy for an open group of maximum eight 
pregnant women, as described in the GMT treatment protocol [47]. The treatment focuses 
on reducing stress, depressive and anxiety symptoms and preparing for the emotional and 
practical impact of motherhood. At the start of the treatment each woman formulates individual 
treatment goals, which she shared with the other group members. The treatment consisted of 
the following consecutive components of one hour: 1) weekly evaluation of treatment goals 
and enhancing social support at home by a social psychiatric nurse; 2) psycho-education by a 
perinatal psychiatrist, with a focus on recognizing and interpreting psychiatric symptoms and 
stimulating healthy behavior; 3) cognitive behavioral therapy (CBT) by a clinical psychologist 
aiming at strengthening coping strategies, problem-solving techniques and avoiding potential 
stressful situations; 4) body-oriented therapy by an Infant Mental Health specialist, focusing 
on increasing maternal mentalization and stimulating bonding to the unborn child, and 5) 
expressive and relaxation therapy by a creative arts therapist, who provides women with 
several techniques and activities to find distraction and reduce stress when they are at home.
The content changed every week. Content was adapted to the needs of the participants, but 
also covered recurring themes like ‘preparing for motherhood and delivery’.
TAU comprised low frequent, individual counseling sessions for approximately 1 contact hour 
provided by a social psychiatric nurse or a medical doctor at the outpatient clinic for perinatal 
psychiatry at the Erasmus MC. This could be on a weekly to monthly basis, based on an 
assessment of the patient’s needs. The primary goal of the counseling is providing psycho-
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education, emotional and practical preparation for motherhood and enhancing social support 
at home. 
In both conditions, if necessary, patients were seen by a psychiatrist to monitor psychiatric 
symptoms and, if applicable, evaluate the effect of psychiatric medication. Median number of 
sessions for both treatment conditions was 4 (range 1 – 23) during pregnancy.  
 
Outcomes and data collection 
The primary outcome was the change of the Edinburgh Depression Scale (EDS) score at 
6 weeks postpartum. The EDS is a 10-item self-report questionnaire that is validated to 
measure depressive and anxiety symptoms during pregnancy (score range: 0-30). Secondary 
outcomes were a) the score of the Hamilton Depression Rating Scale (HDRS) at 6 weeks. 
The HDRS was added as a clinician-rated scale to assess depressive symptoms based on 
17-items (score range: 0-52) [50]. Other secondary outcomes were b) obstetric outcomes 
e.g. perinatal (gestational diabetes, pre-eclampsia, pregnancy-induced hypertension or 
suspected fetal distress) and postnatal complications (neonatal or maternal hospitalization), 
mode of delivery, gestational age, birth weight and pain relief during delivery; and c) Patient 
satisfaction expressed as a weekly mark ranging from 1= not at all to 10= most satisfactory on 
the treatment. Weekly scores were averaged per patient.
Participant and clinician completed the EDS and HDRS at baseline, 5, 10 and 15 weeks 
after treatment onset. Assessments were conducted due to personal contact at the outpatient 
clinic, or by telephone or via postal questionnaire and the preferences of the participants 
were taken into account. Treatment satisfaction was assessed weekly for which participants 
received a text message as a reminder. Demographic characteristics, baseline EDS and 
HDRS were assessed before randomization. At 6 weeks postpartum, a researcher collected 
the EDS, HDRS, obstetric outcomes and treatment satisfaction during a home-visit interview. 
Demographic characteristics, psychiatric history, compliance, obstetric outcomes were 
collected from the electronic patient records. 
We expected a small to moderate treatment effect (eta2 of 0.05 to 0.10 of time x treatment 
interaction) on affective symptoms (measured using the EDS) for women in the randomized 
condition [19]. To demonstrate this (with an alpha of 0.05 and beta of 0.80), we needed a 
sample size of 96 pregnant women per arm (192 in total). We aimed at inviting 275 pregnant 
women for participation in the RCT and preference group, adjusting for a 30% of participants 
not willing to consent for study participation. No a priori power calculation was performed with 
regards to the estimated treatment effect for women in the patient-preference conditions.
Statistical analyses
Baseline characteristics were compared between the randomized condition and patient-
preference condition. Continuous variables (EDS and HDRS-scores on baseline, maternal and 
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gestational age) were tested using T-tests; categorical variables (parity, planned pregnancy, 
marital status, ethnicity, educational level, employment status, psychiatric diagnosis, 
personality disorder, previous episode of depression and/or anxiety, psychotropic medication 
use, smoking, alcohol and illicit drug use) were tested using Chi2-tests. As primary analysis 
we estimated the change of EDS and HDRS scores over time between the randomized and 
patient-preference condition as well as between the randomized GMT and TAU conditions 
using generalized linear mixed modelling analysis. In the random-intercept model we included 
time, treatment allocation (GMT vs. TAU or randomized vs. patient-preference), and the time x 
treatment allocation interaction, as well as the standardized baseline score of EDS or HDRS. 
Regression coefficients including 95% Confidence Interval (CI) and p-value are reported. 
Primary analyses were conducted according to the intention-to-treat (ITT)-principle and 
excluded only participants who lost their pregnancy during the study. By means of sensitivity 
analysis, we repeated our primary analysis using 1) dichotomized outcomes of the EDS 
baseline using cut-off score ≥13 2) on a subsample of the women having an EDS score ≥10 
at baseline [52]; 3) on a subscale of the EDS focusing on anxiety (item 3, 4 and 5) [53]; 4) 
adjusted for age, education level, parity and ethnicity; and a per protocol analysis based on a 
compliance rate of ≥50% attendance [54, 55]. Compliance rate was defined as the proportion 
of attended treatment sessions related to the total number of offered treatment sessions 
during the treatment period. The treatment period is the number of weeks between date 
of informed consent and delivery date, or drop-out date because of withdrawal of informed 
consent or lost to follow-up. Participants were permitted to rebook a session. Differences 
on obstetric outcomes between the randomized and patient-preference condition as well as 
between the randomized GMT and TAU conditions were analyzed using linear (continuous 
outcomes, i.e. gestational age, birth weight) and logistic regression (categorical outcomes, 
i.e. (perinatal and postnatal complications, mode of delivery, prematurity, birth weight and 
pain relief during delivery) outcomes. By means of observational analysis, we repeated the 
analyses comparing GMT versus TAU within the patient-preference condition. Results are 
reported in Supplementary Tables 1 and 2.
To explore whether subgroups of women benefitted more from the treatment, primary analyses 
were repeated in the sample stratified by 1) non-viable gestational age of <24 weeks or ≥24 
weeks; 2) psychiatric disorders e.g. depressive and anxiety disorder; 3) the presence of a 
personality disorder; 4) use of psychotropic medication which may dilute the treatment effect; 
5) ethnicity; and 6) overall treatment satisfaction.
Data was checked for non-normality and outliers. The majority of women were assessed 
three or more times during the study (N=116; 75%). In total, the dataset included 58% of 
EPD, and 52% of HDRS assessments. Patient-preference subsample, and 10 and 15 week 
follow-up assessments showed most missing assessments (54%, 56%, and 81% missing 
assessments, respectively). Missings were mainly due to con-compliance with treatment, 
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drop-out, and incomplete assessments. Non-compliance with treatment and assessment 
schedule increased over the course of pregnancy, as the physical burden of the pregnancy 
increased with the approach of the delivery date. With regards to secondary outcomes 
measures, 29% of data were missing. Missing data on secondary outcomes were handled 
using multiple imputations. Ten imputed datasets were created and all predictor and outcome 
variables were used for imputation modelling. We report pooled estimates [56]. Analyses were 
performed using SPSS 24.0.
resulTs
Figure 1 - Flow chart of the study
Randomization           
N = 99 (63%)  Patient-preference 
N = 59 (37%) 
Exclusion (N=20), reasons: 
- no informed consent (N=14) 
- practical reasons (N=4) 
- hospitalization (N=2) 
Exclusion (N=3), reasons: 
- intrauterine fetal death (N=2) 
- abortion (N=1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: 
* Intention-to-treat analysis 
** Non-compliance is defined as less than 50%, the percentage of treatment sessions within the potential treatment period in weeks between delivery date and date of 
informed consent. Drop-out is defined as withdrawal of informed consent or lost to follow-up.  
 
 
 
Total number of included patients (12-33 
weeks of gestation) with a mental disorder 
 N = 158 (89%) 
GMT 
N = 52 (53%) 
 
Total number of screened patients 
N = 178 
ITT * 
N = 52 (100%) 
 
TAU 
N = 47 (47%) 
 
GMT 
N = 33 (56%) 
 
TAU 
N = 26 (44%) 
(44% 
ITT * 
N = 46 (98%) 
 
ITT * 
N = 31 (94%) 
 
ITT * 
N = 26 (100%) 
 
Per protocol 
N = 21 (40%) 
Per protocol 
N = 14 (30%) 
 
Per protocol 
N = 16 (52%) 
 
Per protocol 
N = 5 (19%) 
 
Non-compliant (N=30) 
Drop-out (N=1) ** 
 
Non-compliant (N=31) 
Drop-out (N=1) ** 
 
Non-compliant (N=12) 
Drop-out (N=3) ** 
) 
 
Non-compliant (N=14) 
Drop-out (N=4) ** 
 
 
Flowchart and demographic characteristics
Figure 1 displays the flow chart of the study. A total of 158 participants were included in 
the study, 99 (63%) participants consented to randomization; and 59 (37%) participants 
declined randomization but agreed to participate in the patient-preference condition. One 
participant terminated her pregnancy at a gestational age of 20 weeks and two pregnancies 
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resulted in fetal death. We included 155 participants in the intention-to-treat (ITT)-analysis, 98 
participants from the randomized group and 57 participants from the non-randomized group. 
Non-compliance and drop-out did not differ between the randomized groups (GMT 40.3% vs. 
TAU 30.4%, p=0.29). Compliance was comparable between the randomized condition (35/98 
participants, 35.7%) and patient-preference condition (21/57 participants, 36.8%). There 
were no baseline differences between participants who were non-compliant or dropped-out 
and those who were included in the per protocol analysis, only participants with a planned 
pregnancy were less likely to be compliant (p=0.03). 
Table 1 shows the baseline characteristics for each of the four conditions. Presented 
characteristics showed no significant differences between the randomized and patient-
preference condition, with the exception that the randomized condition composed more 
primiparae. Participants who planned their pregnancy were more likely to choose GMT, 
instead of TAU. A major depressive disorder was diagnosed in 46.2% of all participants 
and one third suffered from an anxiety disorder. Almost half (49.4%) of the participants met 
criteria for a personality disorder and most prevalent were Cluster B disorders, e.g. borderline 
personality disorder. Half (50.0%) of the participants reported a history of two or more 
episodes of an anxiety disorder or depression. More than one third (38.6%) of all participants 
used psychotropic medication during the treatment. There were no differences in baseline 
symptomatology score on EDS or HDRS between the randomized and patient-preference 
condition, and between GMT and TAU in the patient-preference condition.
Treatment effect after six weeks postpartum 
Table 2 shows the regression coefficients for EDS scores for the primary outcome, various 
subgroups and sensitivity analysis. In the randomized condition, GMT was not superior above 
TAU according to estimated EDS (β=0.13, CI=-0.46 – 0.71, p=0.67) and HDRS scores (β=-0.39, 
CI=-0.82 – 0.05, p=0.08). There were no differences in observed mean EDS and HDRS scores 
in the randomized condition compared to the patient-preference condition. The sensitivity 
and subgroup analysis supported the findings of our primary analysis. None of the sensitivity 
or subgroup analysis (stratification, psychiatric disorder, personality disorder, psychotropic 
medication, ethnicity, substance use and treatment satisfaction) were significantly different 
between GMT and TAU, neither randomized vs. patient-preference condition. Observational 
analyses (reported in Supplementary Table 1) show no differences between GMT and TAU of 
the estimated means for EDS scores for the primary outcome, and with regards to sensitivity 
and subgroup analyses.  
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Table 1 – Demographic and clinical characteristics of 158 included participants in the study
   
GMT 
N = 52
RANDOMIZED PATIENT-PREFERENCE PATIENT-
PREFERENCE
GMT VS. TAU
RANDOMIZED
 VS. PATIENT-
PREFERENCE
TAU
 N = 47
GMT
 N = 33
TAU
 N = 26
Demographic 
characteristics
Mean (SD) Mean (SD) Mean (SD) Mean (SD) p-value p-value
Maternal age (years) 29.4 (4.5) 30.8 (5.5) 30.8 (5.5) 30.4 (4.4) 0.76 0.52
Gestational age (weeks) 21.1 (6.1) 21.1 (6.7) 19.8 (5.5) 22.5 (6.4) 0.08 0.94
N (%) N (%) N (%) N (%)
First child  33 (63.5) 25 (53.2) 17 (51.5) 7 (26.9) 0.06 0.03
Planned pregnancy 33 (63.5) 24 (51.1) 22 (66.7) 8 (30.8) 0.006 0.41
Marital status
  Married/co-habiting 43 (82.7) 36 (76.6) 26 (78.8) 21 (80.8) 0.99 0.98
Ethnicity
   Caucasian 46 (88.5) 36 (76.6) 26 (78.8) 18 (69.2) 0.55 0.21
Education level
  Low education level 40 (76.9) 31 (66.0) 21 (63.6) 19 (73.1) 0.58 0.60
Employment status
  Unemployed 43 (82.7) 28 (59.6) 27 (81.8) 17 (65.4) 0.15 0.70
Clinical characteristics N (%) N (%) N (%) N (%)
Axis 1 Psychiatric 
disorder
  Depressive disorder
  Anxiety disorder 
  Psychotic disorder 
  Other a  
  No Axis 1 disorder
26 (50.0)
14 (26.9)
2 (3.8)
1 (1.9)
9 (17.3)
23 (48.9)
15 (31.9)
1 (2.1)
2 (4.3)
6 (12.8)
12 (36.4)
11 (33.3)
1 (3.0)
2 (6.1)
7 (21.2)
12 (46.2)
10 (38.5)
0 
2 (7.7)
2 (7.7)
0.55 0.64
Axis 2 Personality 
disorder
  Cluster A
  Cluster B
  Cluster C
  No personality disorder
1 (1.9)
19 (36.5)
4 (7.7)
28 (53.8)
1 (2.1)
13 (27.7)
7 (14.9)
26 (55.3)
0
13 (39.4)
7 (21.2)
13 (39.4)
0
8 (30.8)
5 (19.2)
13 (50.0)
0.71 0.18
Previous episode of 
anxiety/depressionb
  ≥ 2 episodes
  None 
9 (17.3)
31 (59.6)
12 (23.1)
12 (25.5)
21 (44.7)
14 (29.8)
14 (42.4)
14 (42.4)
5 (15.2)
5 (19.2)
13 (50.0)
8 (30.8)
0.12 0.31
Psychotropic medication 
use
  SSRI/nSRI/TCA
  Antipsychotics
  Lithium  
  Benzodiazepines
  Other c
  None
14 (26.9)
1 (1.9)
0
1 (1.9)
1 (1.9)
35 (67.4)
16 (34.0)
0
3 (6.4)
1 (2.1)
0
27 (57.5)
15 (45.5)
1 (3.0)
0
0
0
17 (51.5)
8 (30.8)
1 (3.8)
0
0
0
17 (65.4)
0.50 0.34
Smoking in pregnancy d 19 (36.5) 18 (38.3) 16 (48.5) 8 (30.8) 0.17 0.68
Alcohol in pregnancy  d  13 (25.0) 13 (27.7) 8 (24.2) 5 (19.2) 0.65 0.55
Illicit drug use  d 6 (11.8) 2 (4.3) 3 (9.1) 2 (7.7) 0.85 0.95
Symptomatology at 
baseline
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
EDS score 14.4 (7.5) 15.9 (7.5) 14.8 (7.0) 15.7 (8.1) 0.65 0.96
HDRS score 11.8 (5.8) 11.6 (5.7) 10.6 (6.4) 12.0 (5.0) 0.38 0.63
Note: 
a Includes: eating disorder and ADHD
b An episode of anxiety or depression which needed treatment
c Includes: ADHD medication
d Any exposure during pregnancy
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Table 3 shows the obstetrical outcomes for the four conditions. There were no significant 
differences on this secondary outcome between GMT and TAU, nor for the randomized versus 
the patient-preference condition. Supplementary Table 2 shows the observational analysis in 
the patient-preference condition for the obstetrical outcomes. Participants who chose GMT 
were more likely to deliver a child with a lower birth weight. The higher number of primiparae 
in the patient-preference GMT condition might have confounded this result.
Weekly report of treatment satisfaction marks showed an overall moderate satisfaction 
with a mean mark ranging from 6.8-7.1 for the GMT. Satisfaction marks did not significantly 
differ between GMT (6.8±1.9) and TAU (7.2±1.1, p=0.28). Women in the patient-preference 
condition were not significantly more satisfied with the chosen treatment condition, compared 
to women in the randomized condition. The subgroup analysis for a low satisfaction mark (<6) 
did not show to be significantly different between GMT and TAU, nor between the randomized 
versus patient-preference condition. 
Figure 2 depicts the profiles of estimated mean EDS scores during the first 15 weeks of 
treatment period and 6 weeks postpartum, for the randomized condition (figure 2A) 
and the patient-preference condition (figure 2B). EDS follows the same pattern in all four 
groups resulting in a steadily decrease during treatment period and a further decrease in 
the postpartum period to an estimated mean score below the cut-of value ≤13 at 6 weeks 
postpartum for all conditions. 
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Figure 2 - Profiles of estimated means of Edinburgh Depression Scale (EDS) scores including confidence 
intervals during treatment period, GMT vs. TAU (figure 2A) and randomized vs. patient-preference 
condition (figure 2B)
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3
discussion
This is the first randomized controlled trial among a clinical sample of pregnant women 
with co-morbid psychiatric and psychosocial problems, mainly reflected in low SES (i.e. low 
educational level and/or high unemployment), that compared a Group-based Multicomponent 
Treatment (GMT) to individual counseling for the reduction of depressive symptoms during 
pregnancy. Overall, there was no significant difference observed in decrease of depressive 
symptoms between GMT and treatment as usual (TAU). 
A major strength of our study is that we were able to successfully recruit a hard-to-reach 
population; only 20 (11.2%) eligible women refused participation, almost two out of three 
women willing to participate consented to randomization and drop-out was low (9/155, 5.8%). 
Included women were next to major depressive disorder, also diagnosed with a high number 
of anxiety disorder (31.6%) and a comorbid personality disorders (49.4%). We believe that 
this heterogeneity reflects clinical practice and this enhances the generalizability of our results 
to other clinical populations. Strength of the study design is that it allowed us to additionally 
investigate the effect of patient’s preference for group-based or individual therapy on treatment 
response [57]. Since there were no differences in baseline characteristics, compliance, drop-
out and outcomes between the randomized and patient-preference condition, also in this 
respect the results of our study support generalizability to clinical practice [48].
In comparison with other studies focusing on reducing depressive symptoms during pregnancy, 
a few small RCT’s have been carried out which confirmed that individual CBT is effective for 
prenatal depression [22, 58]. One group-based RCT (n=191) showed a significant beneficial 
effect for the CBT group in the completers group compared to a booklet group [20]. In line 
with three other medium-sized RCT’s (n=34-55), we found no significant differences in overall 
decrease of depressive symptoms after the treatment between the intervention and control 
group [21, 59, 60]. One possible explanation is that our sample size was too small; unfortunately 
this is reality in this hard-to-reach population. Exclusion, drop-out and non-compliance was 
not associated with patient characteristics, presumably this has not lead to a selection bias, 
however the feasibility of an RCT within this population continues to be an issue [42, 43]. Also, 
we missed more than half of the 10 and 15 week follow-up assessments during pregnancy 
and this may have limited the study to detect a direct treatment effect. These missing data due 
to the low compliance are comparable with other studies for depression during pregnancy for 
a low-income population, as well for IPT [24, 61] as CBT [21, 60]. However, generalized mixed 
model analysis is robust for missing values. Sensitivity analyses supported the validity of our 
findings and showed no differences in the ITT and per protocol analysis. It is questionable 
whether a larger sample size had ensured an effect; we think it might also be related to the 
ceiling effect of our TAU. The treatment as usual was offered in a specialized tertiary center 
for perinatal mental illness with experienced clinicians and this tailored treatment could be 
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as effective as GMT. We limited our outcome measurement to depression scores based on 
the validated EDS and it is questionable whether the EDS thoroughly assess also comorbid 
anxiety symptoms [53]. Since we did not investigate other potential benefits of GMT above 
TAU, like improvement of lifestyle, social support or maternal mentalization or bonding to the 
unborn child, we cannot exclude that women improved on other domains, or the GMT missed 
to specifically address the mental health concerns of specific disorders.
Based on our study, we recommend that further research on antenatal therapies treating 
depression should also focus on co-morbid psychiatric and psychosocial problems, like 
personality disorders, low SES, social support and life style. For example, our previous study 
focusing on the role of psychiatric and psychosocial problems on birth outcomes showed that 
low SES and the accumulative effects of psychiatric and psychosocial risk factors have bigger 
impact on decreased birth weight and preterm birth above depressive symptoms [39]. 
In conclusion, our Group-based Multicomponent Treatment (GMT) showed to be a 
feasible treatment for a clinical sample of pregnant women with co-morbid psychiatric and 
psychosocial problems. We could not demonstrate that GMT is more effective than individual 
counseling. Both interventions could be ineffective or the effect of a natural course. A new 
(multicomponent) treatment should ideally be compared with a golden standard. However, 
evidence is inconclusive or not eligible for this heterogeneous group [18]. NICE guidelines 
recommend for women with a moderate or severe depression in pregnancy a high intensity 
psychological intervention (for example, CBT) [62]. Depending on local availability and costs, 
clinicians should consider and discuss different treatment options, taking into account personal 
circumstances and preferences of the patient. 
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Supplementary Table 1 – Observational patient-preference analysis: Estimated means of Edinburg 
Depression Scale (EDS) at six weeks postpartum between GMT vs. TAU ^
PATIENT- PREFERENCE GMT vs. TAU
GMT
N = 33
TAU
N = 26
β # (95% CI) p-value
Primary outcome: EDS mean (SE) 10.4 (1.3) 10.0 (1.6) 0.06 (-0.96 – 1.08) 0.91
Hamilton Depression Rating Scale 
mean (SE) 
7.1 (1.0) 5.1 (1.1) 0.51 (-0.24 – 1.25) 0.18
Sensitivity analysis
  Estimated mean EDS score (SE) GMT TAU β # (95% CI) p-value
Dichotomised outcome (cut-off 
EDS<13) (estimated proportion 
below cut-off, SE)
0.79 (0.1) 0.84 (0.1) 0.08 (-0.39 – 0.54) 0.74
Inclusion criterion of baseline cut-off 
score ≥10 on EDS
10.9 (1.4) 11.8 (1.7) -0.10 (-1.27 – 1.08) 0.87
EDS anxiety subscale 4.5 (0.5) 4.8 (0.6) -0.10 (-0.47 – 0.27) 0.58
Adjusted mean score * 10.2 (1.4) 9.6 (1.7) 0.06 (-0.98 – 1.09) 0.92
Per Protocol mean score ** 11.6 (2.0) 12.2 (3.2) -0.05 (-2.06 – 1.97) 0.96
Subgroup analysis
  Estimated mean EDS score (SE) GMT TAU β # (95% CI) p-value
Stratification based on gestational 
age at inclusion: <24 weeks
	≥24 weeks
9.0 (1.4)
17.8 (3.3)
5.1 (2.5)
14.2 (2.0)
0.47 (-0.84 – 1.81)
0.85 (-1.14 – 2.85)
0.47
0.39
Categorized by psychiatric disorder:
	depression
	anxiety
8.5 (2.4)
11.9 (1.8)
11.4 (2.2)
9.8 (2.5)
-0.80 (-2.54 – 0.94)
0.26 (-1.33 – 1.85)
0.36
0.74
Presence of personality disorder:
	no personality disorder
8.3 (1.6)
12.4 (1.9)
11.9 (2.4)
8.7 (2.0)
-0.90 (-2.20 – 0.40)
0.30 (-1.09 – 1.68)
0.17
0.67
Psychotropic medication use:
	no use
8.9 (1.8)
12.5 (1.8)
8.5 (2.5)
10.8 (1.9)
-0.12 (-1.17 – 1.43)
0.38 (-0.87 – 1.62)
0.87
0.55
Caucasian ethnicity:
	non-Caucasian
9.7 (1.3)
12.4 (3.4)
10.3 (1.8)
10.9 (3.1)
-0.31 (-1.41 – 0.80)
0.55 (-1.99 – 3.08)
0.59
0.66
Patients treatment satisfaction on a 
weekly mark: ≥6 8.7 (1.2)
 
9.6 (2.3) -0.25 (-1.47 – 0.97) 0.69
Note: 
^ Generalized linear mixed model including time, treatment allocation and baseline score of EDS/HDRS, 
reported in regression coefficients with confidence intervals and p-values
# Difference between GMT vs. TAU in the patient-preference condition, TAU is reference condition. 
* Adjusted for age, ethnicity, education level, and parity.
** Per protocol analysis is based on ≥50% compliance during treatment period.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 3
76
Supplementary table 2 – Secondary outcome observational analysis
PATIENT-PREFERENCE GMT vs. TAU
GMT
N = 33
TAU
N = 26
β #  (95%CI) p-value
Perinatal complication*
Any complication                                        
Fetal distress 
N (%)
17 (51.5)
8 (24.2)
N (%)
12 (46.2)
6 (23.1)
1.39 (0.47 – 4.15)
1.14 (0.26 – 5.04)
0.56
0.86
Mode of delivery:                                    
Spontaneous vaginal delivery                     
Instrumental vaginal delivery 
Caesarean section  
24 (72.7)
4 (12.1)
5 (15.2)
14 (53.8)
4 (15.4)
8 (30.8)
2.25 (0.59 – 8.51)
0.82 (0.14 – 4.81)
0.38 (0.07 – 1.92)
0.24
0.82
0.24
Pain relief during delivery 21 (63.6) 17 (65.4) 0.86 (0.25 – 3.04) 0.82
Gestational age, mean (SD)
   Premature birth (<37 weeks)
34.5 (2.3)
6 (18.2)
39.0 (1.6)
3 (11.5)
0.59 (0.15 – 2.28)
2.28 (0.32 – 12.86)
0.62
0.46
Birth weight in grams, mean (SD)**
   SGA (p<10)
3288 (470)
3 (0.9)
3559 (671) 
4 (15.4)
0.69 (0.48 – 0.99)
-
0.048
0.99
Postpartum complication***
 Any complication 7 (21.2) 5 (19.2) 0.98 (0.24 – 4.00) 0.98
Note:
#  Difference between GMT vs. TAU in the patient-preference condition, TAU is reference condition. 
* Perinatal complications were grouped as: gestational diabetes, pre-eclampsia, pregnancy-induced 
hypertension, hospitalization >24 hour or suspected fetal distress (diagnosed on the basis of a pH < 7.2 
on a fetal blood sample during delivery or Apgar score <7 after 5 minutes) 
** Birth weight obtained from obstetric records (recorded in grams); small-for-gestational-age (SGA) 
determined using birth weight adjusted for gestational age, parity and fetal gender. SGA could not be 
calculated. 
*** Postpartum complications included hospital admission, 6 weeks postpartum women were asked 
whether the patient or baby had been hospitalized in the first 6 weeks after delivery.
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aBsTracT
Objective: Disturbed sleep during pregnancy is associated with adverse obstetric outcomes 
and less mental well-being. In pregnant women with a mental disorder, who frequently suffer 
from sleep problems, it is unknown whether predominantly objective or subjective sleep 
quality is more affected. To clarify this, we compared objective and subjective parameters of 
sleep quality between patients and healthy controls during pregnancy.
Methods: This observational study was embedded in an ongoing study among pregnant 
women with a mental disorder at the department of Psychiatry of Erasmus University Medical 
Center Rotterdam, the Netherlands. We compared 21 pregnant women with a confirmed 
mental disorder with 33 healthy controls (gestational age, 23-29 weeks). To measure objective 
parameters of sleep quality, all participants continuously wore a wrist actigraph for 7 days 
and nights. Subjective sleep quality was retrospectively assessed using the Pittsburgh Sleep 
Quality Index (PSQI) and on a daily basis with the Subjective Sleep Quality-scale (SSQ). 
Differences in parameters of sleep between patients and controls were tested using a 
multivariate linear regression analysis adjusted for parity, gestational age, educational level, 
and employment status.
Results: Objective parameters of sleep quality and subjective sleep quality as assessed by 
the PSQI did not differ significantly between patients and controls. Daily sleep reports showed 
that, relative to controls, patients had a significantly worse average SSQ-score (5.2 vs. 7.6, 
adjusted β=0.12, 95%CI = 0.03-0.53, p<0.01).
Conclusions: Our exploratory study suggests that perceived sleep quality reported on a daily 
basis by pregnant women with a mental disorder is worse than the sleep quality as measured 
by wrist actigraphy.
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inTroducTion 
Approximately one-third of all pregnant women report sleeping problems [1]. Poor sleep quality 
and the persistence of disturbed sleep is associated with less mental well-being and adverse 
obstetric outcomes [2-4]. However, little is known about the causal pathways that explain 
the association between poor sleep quality and adverse obstetric outcomes. For example, 
disrupted sleep can be a (prodromal) symptom of a mental disorder or a consequence of the 
mental disorder [5]. From studies in non-pregnant psychiatric patients compared to healthy 
controls, it is known that a mental disorder is associated with prolonged sleep onset latency, 
increased wake after sleep onset, and reduced sleep efficiency [6-8]. Moreover, having a 
mental disorder itself is associated with adverse birth outcomes [9]. A first step that could 
help to clarify these underlying causal pathways is to investigate whether objective and 
subjective parameters of sleep quality during pregnancy differ between patients and healthy 
controls. Previous studies showed that pregnant women with a depressive disorder report 
more fragmented sleep, as reflected in longer sleep latencies and poorer sleep efficiency, 
than pregnant women without a depressive disorder [10, 11].
Non-pregnant patients with depression and sleep problems also showed discrepancy between 
subjective and objective sleep measurements [12] - e.g., objective sleep quality - as measured 
by actigraphy more closely approximated those of the golden standard (polysomnography) 
than subjective measurements in depressed insomniacs [13]. 
It is unclear whether sleep quality in pregnant women is objectively worse in a sense of reduced 
or fragmented sleep, or whether their perception of it is altered, possibly as a result of co-
occurring psychiatric symptoms. The interpretation of perceived poor sleep quality in pregnant 
women with a mental disorder could help clinicians to determine whether they should primarily 
focus on the perception of sleep quality and treatment of the underlying mental disorder, or 
whether they should intervene on the objective parameters of sleep. To identify sleep quality 
in pregnant women with a mental disorder, we studied both objective (wrist actigraph) and 
subjective (questionnaires) indicators of sleep in patients and in healthy controls during the 
second trimester of their pregnancy.
meThods 
The protocol of this cohort study was, as part of a larger randomized controlled trial (DAPPER, 
NTR3015 http://www.trialregister.nl), approved by the Medical Ethical Committee at Erasmus 
MC Rotterdam. In short, the aim of the DAPPER study is to evaluate the effectiveness of a 
group-based multicomponent psychotherapy intervention for pregnant women with a mental 
disorder, compared to individual counselling. Eligible participants were pregnant women 
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diagnosed with a mental disorder and/or personality disorder, confirmed by a Structured 
Clinical Interview for DSM-IV diagnosis by one trained medical doctor [14]. We chose to recruit 
participants at the end of their second trimester (23-29 weeks of gestation), when sleep quality 
seems to be less affected by the pregnancy itself or by the routine 20-week fetal ultrasound 
examination in Dutch antenatal care, which can be potentially stressful. Through contact with 
4 community midwifery practices in Rotterdam, we recruited pregnant women (1) without 
current psychiatric symptoms on the Brief Symptom Inventory [15] (BSI, global severity index 
score: <0.71) and (2) without psychotropic medication use. Participants were excluded if they 
suffered from a tremor or medical conditions that could affect sleep (e.g., sleep apnea) or 
were unable to read or write in Dutch. Once written informed consent had been obtained, all 
participants provided demographic information. A low educational level was defined as: no 
education, only attending primary school or finished secondary school on the lowest level. 
Objective parameters of sleep were measured using the Actiwatch Actigraphy model AW4 
(Cambridge Neurotechnology Ltd, UK). Agreement of the Actiwatch Actigraphy model AW4 
with the golden standard (polysomnography) has been demonstrated [16], though not in 
a population of pregnant women. When placed on the non-dominant wrist, the Actiwatch 
measures the number of movements above a certain threshold per 60-s epoch, and provides 
the following indices: total sleep time (TST); sleep latency (time until asleep); sleep efficiency 
(percentage of time spent asleep while in bed); and the fragmentation index (percentage 
immobility phases of one minute). Sleep data were analysed using the Actiwatch Sleep Analysis 
program (Version 1.16, Cambridge Neurotechnology Ltd, UK). Although all participants wore 
an Actiwatch for 7 consecutive days and nights, only the weekdays (≥3 days and nights) 
were used for analysis because of the increase in variability during the weekends and also in 
agreement with recent literature [17-19]. The precision of the 5-weekday assessment period 
was better than for 7 days and did not differ between the groups. Correlation of the 5-weekday 
assessment period was moderate for the actigraphically measured TST (ICC=0.60) and 
sleep latency (ICC=0.51), and good for sleep efficiency (ICC=0.76) and sleep fragmentation 
(ICC=0.68) for all participants. The correlation for the subjective parameters was weaker than 
the actigraphically measured parameters; the ICCs for TST, sleep latency, and SSQ were 
respectively 0.48, 0.46, and 0.46. 
Subjective sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI), a 
self-rating questionnaire that measures sleep quality and disturbances retrospectively over a 
1-month period. The PSQI scoring method produces an overall score between 0 and 21, with 
higher scores indicating poorer sleep quality [20]. A PSQI-score ≥5 is considered the cutoff 
point, which discriminates a good sleeper (<5) from a poor one. Relative to a combination of 
clinical interviews and polysomnographic measures, the threshold of ≥5 yields a diagnostic 
sensitivity of 89.6% and a specificity of 86.5% [21]. The PSQI has good validity in depressed 
and pregnant populations [22]. By analogy with the actigraphically measured parameters, we 
included two specific PSQI-domains: sleep latency and sleep efficiency. 
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Participants kept a daily sleep diary for one week and received a text message to remind 
them to fill it in after breakfast. The diary included questions on total sleep time, sleep latency, 
and the Subjective Sleep Quality scale (SSQ), an 11-item true-or-false questionnaire that 
culminates in a sum score of between 0 and 11, with higher scores indicating good sleep 
quality [23].
By analogy with the actigraphically measured parameters, a minimum of 3 weekday dairies 
of each participant were averaged, based on a threshold setting of 20 activity counts within a 
1-min epoch for the analysis of the Actiwatch data. The number and length of naps during the 
day were not included in the TST calculations of the diary or in the actigraphically measured 
TST.
Data Analysis
Differences on demographic characteristics (age, gestational age, parity, family status, 
ethnicity, educational level, employment and the percentage of available weekday data) 
between patients and controls were tested using T-tests (continuous variables) or χ2 tests 
(categorical variables). Actigraphically measured parameters and SSQ-scores were averaged 
over ≥ 3 weekday nights for each participant. All parameters of sleep were tested for normality 
using Q-Q plots and histograms; variables that violated the assumption of normality were 
logtransformed to resemble a normal distribution. Differences in sleep parameters between 
patients and controls were tested using univariate and multivariable linear regression 
analyses, adjusting for parity, gestational age, education level, and employment status. Beta 
values (95% CIs) are reported and a twosided p-value of <0.05 was taken as statistically 
significant. A total sample size of 52 participants allows for the detection of large effect sizes 
(≥0.8) with a significance level of 0.05 and a power of 0.80 [24]. Data were analysed using 
SPSS (version 20) for Windows.
resulTs
Patients were diagnosed with a current unipolar major depressive disorder (n=12), 
generalized anxiety disorder (n=6), personality disorder (n=2), or bipolar disorder (n=1). None 
of the participants used sleep medication; one patient with depression used an SSRI during 
pregnancy. Patients had a significantly lower educational level, and significantly more of them 
were unemployed than controls (Table 1). Other demographic characteristics did not differ. All 
participants completed the protocol. The percentage of analysed weekday nights out of the total 
nights collected did not differ between the groups, not for the Actiwatch data (patients 92% vs. 
controls 97%, p=0.15) nor for the sleep diaries (patients 92% vs. controls 97%, p=0.09). There 
were no significant differences between patients and controls in the actigraphically measured 
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parameters of sleep (Table 2). Patients reported longer sleep latency than controls and had 
a significantly poorer average score on the Subjective Sleep Quality Scale in the diaries. The 
SSQ-score remained significantly different between patients and controls after adjustment 
for parity, gestational age, educational level, and employment status. Sleep quality reported 
retrospectively over a 1-month period (PSQI-score) did not remain significantly different after 
adjustment, although in the crude analysis, a significantly larger proportion of patients scored 
above the non-adjusted threshold of a poor sleeper (patients 81% vs. controls 39%, p<0.01). 
The disagreement between the actigraphically measured and diary-reported TST was larger 
in patients (mean=1:25h; Bland-Altman 95% limits of agreement (LA) between 0:11 to 3:01) 
than in controls (mean=1:14h; LA between 0:12 to 2:20) [25]. A similar trend was observed 
regarding sleep latency and sleep efficiency.
Table 1 - Demographic characteristics of all participants at start of study.
Patients (n = 21)
Mean (SD)
Controls (n = 33) 
Mean (SD)
Significance
p-value
Age 29.8 (5.2) 30.4 (3.5) 0.64
Gestational age in weeks 25.7 (1.7) 25.0 (1.4) 0.14
Parity   - Nullipara 15  (71%) 17 (52%) 0.15
Family status    - Married  19  (91%) 32 (97%) 0.31
Ethnicity    - Immigrant 5    (24%) 3 (9%) 0.14
Educational level    - Low 14  (67%) 7 (21%) <0.01
Employment           - No 14  (67%) 3 (9%) <0.01
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discussion 
Our results indicate that subjective sleep quality as measured on a daily basis by the SSQ was 
significantly worse in pregnant women with a mental disorder than in those without a mental 
disorder. There was no significant difference regarding the objective parameters of sleep. 
In all participants, actigraphically measured TST was lower than the diary-reported TST. 
This is consistent with other studies reporting similar discrepancies between actigraphically 
measured TST and subjective perception of TST among non-pregnant insomnia sufferers 
and normal sleepers [26]. Recently, Herring and colleagues showed that the discrepancy 
between actigraphically measured and self reported TST in a majority of 80 healthy pregnant 
women was over one hour [27]. While our study confirms this finding, it also suggests that 
this discrepancy is greater in patients than in controls. Despite this discrepancy, it is worth 
noting that all participants’ average actigraphically measured TST (6:40h) was shorter than 
that recorded in earlier studies in pregnant women (7.1-7.8h) [3, 28, 29]. The suboptimal sleep 
quality in pregnant women is also reflected by the overall less favourable scores on the PSQI.
This study has several limitations. First, our study is subject to limited power to detect small 
and medium effect sizes; as a consequence of that, we cannot exclude a type II error in our 
findings. However, our subjective measures did reach significance within the same sample 
size. Secondly, due to our small sample we had to group all mental disorders together and 
could therefore not make a statement for each mental disorder separately during pregnancy. 
We also acknowledge that the Actiwatch AW4 model is not validated against polysomnography 
in a population of pregnant women and that there are large differences in sleep variables 
between different brands of actigraphs and settings [30]. At last, we did not match for the 
daytime activities and level of education between patients and controls, although significantly 
more healthy controls were employed and highly educated. However, after adjusting for 
employment and level of education, as well as for the confounders parity and gestational age, 
the difference between subjective sleep quality as measured by the SSQ remained significant. 
Despite these limitations, this study is one of the first in a clinical population to find that a 
mental disorder during pregnancy is more associated with poorer subjective sleep quality than 
with changes in parameters of objective sleep quality. Our results demonstrate the importance 
of focusing on the perception of sleep in pregnant women with a mental disorder who report 
sleep problems. Although this is an exploratory study, we speculate that these women might 
benefit from cognitive behavioural therapy, as demonstrated in studies with non-pregnant 
participants [31-33].
Future research should focus on whether the association between perceived poor sleep quality 
and adverse birth outcomes that has been found in previous studies is independent or could 
be explained by co-occurring psychiatric symptoms. Also, the consequences of perceived 
poor sleep quality during pregnancy for persistence or recurrence of mental disorders in the 
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postpartum period has to be investigated in women with a known mental disorder. For example, 
Park et al. recently showed that subjective perception of sleep quality of healthy pregnant 
women is a stronger predictor of depressive symptoms postpartum than actigraphy measures 
[34]. Although previous research has shown a clear association between postpartum reduced 
sleep and the occurrence or exacerbation of affective and psychotic disorders, little is known 
about whether these women are already at increased risk during pregnancy [10, 35].
Perinatal health-care professionals should be aware that overall sleep quality is reduced during 
pregnancy and should explain to their patients that this particularly concerns sleep perception. 
Cautious use of sleep medication (e.g., benzodiazepines) is recommended because of the 
potential risks for the fetus and the risk of addiction of the mother. Also, additional risks exist 
in women with sleep apnea. One exception to this involves pregnant women with a bipolar 
disorder or past or current psychosis, in whom sleep plays a crucial role in the prevention of 
postpartum psychosis [36].
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aBsTracT
Purpose: In pregnant women with a mental disorder, we observed mood fluctuations 
rather than chronic depressed mood. This pilot study aims to describe phenotypes of mood 
fluctuations across pregnancy, and to test if repeated measurement of mood contributes to a 
better understanding of the psychopathology. Furthermore, we explored if mood fluctuations 
are related to pregnancy outcomes and depressive symptomatology in the postpartum period.
Methods: We included a clinical convenience sample from a perinatal psychiatry outpatient 
clinic of a tertiary center in our study. Ninety-nine pregnant women met DSM-IV criteria of a 
mental disorder with clinical relevant symptoms based on the cut-off score of the Edinburg 
Depression Scale (EDS) and Hamilton Depression Rating Scale (HDRS) were included in 
this study. Women were asked to fill in a Profile of Mood State (POMS) in a weekly diary 
across pregnancy. The POMS assesses current feelings of depression, tension, anger, 
fatigue, vigour and together this represent the overall mood state (Total Mood Disturbances). 
We described three phenotypes of mood patterns over time: severe mood fluctuations, 
stable negative (more depressed/anxious) or stable positive mood (reference group). The 
demographic variables, pregnancy outcomes and postpartum depression rates are described 
of the different phenotypes. 
Results: A lower birth weight was found in the phenotype with mood fluctuations, compare to 
the phenotypes with a stable negative or positive mood. We observed no significant differences 
on other demographic, clinical or pregnancy outcomes between the three phenotypes.  
Discussion: In a clinical sample of pregnant women with a mental disorder, we identified a 
phenotype with severe mood fluctuations. This phenotype is also characterized by co-morbid 
psychiatric and psychosocial problems, and these women might be at risk for poor pregnancy 
outcomes. Future studies have to be carried out to further disentangle these findings, using 
repeated measurements of mood and investigate whether severe mood fluctuations result in 
a worse prognosis for mother and the (unborn) child. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Mood fluctuations across pregnancy in women with a mental disorder
93
5
inTroducTion
Mental disorders are a major cause of disability among women during the perinatal period 
and may have consequences for the offspring. Maternal psychopathology includes a broad 
spectrum of mental disorders during pregnancy, mainly depressive and anxiety related 
disorders [1]. It is also known that some pregnant women – with and without psychopathology 
– can show a characteristic pattern of mood fluctuations across pregnancy, likely due to 
hormone and other physical changes. In many pregnant women moodiness flares up around 6 
to 10 weeks, eases in the second trimester, and then reappears as their due date approaches 
and more physical disabilities occur. Mood fluctuations are understood to be relatively benign 
and are described as feelings in the range of depression, tension, anger, fatigue, and lack of 
vigour. 
In clinical practice mood fluctuations are observed in pregnant women with psychopathology, 
regardless of their underlying mental disorder. It is important to know how these mood 
fluctuations evolve and if this is associated with additional risks. This is of clinical importance 
because usually screening for psychopathology happens only once in antenatal care. As a 
snapshot of the current state, we might underestimate the severity of the psychopathology 
and the prognosis. 
To our knowledge, there is no longitudinal study with repeated measurement of mood across 
pregnancy. First, we describe three fictional cases of pregnant women with a mental disorder 
and how their mood states evolve across pregnancy. The aim of this pilot study is primarily 
to describe phenotypes of mood fluctuations across pregnancy by intending a weekly 
assessment of mood states in women with a diagnosed mental disorder. Second, we explored 
if these phenotypes of mood fluctuations are related to pregnancy outcomes and depressive 
mood in the postpartum period.
maTerials and meThods
This pilot study is a clinical convenience sample derived from a randomized controlled trial 
(RCT; DAPPER, NTR3015, www.trialregister.nl), approved by the medical ethical committee 
at Erasmus MC Rotterdam. In short, the DAPPER-trial aimed to evaluate a Group-based 
Multicomponent Treatment (GMT) for pregnant women with a mental disorder, using individual 
counselling as control treatment (TAU) [2]. This RCT showed that there was no difference in 
postpartum mood between the two conditions. 
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Procedure
We recruited pregnant women with a gestational age of >12 weeks at the outpatient clinic 
of the Perinatal Psychiatry Department of the Erasmus University Medical Center, a tertiary 
center in Rotterdam, the Netherlands. Once written informed consent had been obtained, all 
participants provided demographic information; a mental disorder and/or personality disorder 
were confirmed by a Structured Clinical Interview for DSM-IV diagnosis conducted by one 
trained medical doctor [3]. Demographic characteristics, psychiatric history and obstetric 
outcomes were additionally obtained from the electronic patient records. All participants 
received treatment on the outpatient clinic and depending on the severity of their symptoms, 
were also treated with psychotropic medication. 
Assessment of mood and mood fluctuations across pregnancy
Our main interest were mood fluctuations across pregnancy. Every Tuesday, participants were 
asked to fill in a diary in the morning (after breakfast) and evening (before bedtime) after 
they received a text message reminder. The diary included questions about sleep quality, 
daily activity and mood state. Here we used only the morning measurements. The Profile 
of Mood State (POMS) was included in the diary to assess mood. The POMS is originally a 
65-item self-report questionnaire for adults using self-descriptive adjectives that assess the 
state of mind at that time [4]. The Dutch POMS is a shortened version and consists of 32 
items [5, 6], it has been shown to be a reliable tool to measure mood states [7]. Participants 
are asked to indicate on a 5-point Likert scale (0 = not at all and 4 = very good fit) to what 
extent different mood terms resemble their current mood state. The Dutch POMS has five 
subscales: depression, tension, anger, fatigue and vigour. We calculated subscale scores and 
Total Mood Disturbance (TMD)-score as a representation of participants’ overall mood state. 
The TMD-score is computed by adding the negative scales (depression, tension, anger and 
fatigue) and subtracting the positive scale (vigour). Higher scores indicate more disturbed and 
affected mood. 
Mood fluctuation phenotypes
The participants filled in 11 diaries on average. We included data of 959 consecutive morning 
TMD-assessments of 99 women (range: 3-23 assessments, median: 9 assessments). 
Women with less than 3 assessments were excluded from the analyses. For each woman, 
we calculated the mean and standard deviation of all available TMD morning scores. The 
subgroup of women in the highest variability in their TMD morning scores was determined 
using the standard deviation of their individual TMD scores. Women were categorized in three 
categories. Women in the highest tertile (with a standard deviation of 2.86 or higher) were 
labelled as suffering from ‘severe mood fluctuations’. The remaining women were dichotomized 
into stable negative and stable positive mood subgroups using median split of their mean TMD 
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morning score (cut off score=1.70). The POMS scores were normally distributed for each 
phenotype. The number of diaries did not differ between the three phenotypes. Subscales of 
the POMS correlate highly (ranging from 0.75 to 0.90). The reliability of the categorization was 
checked by creating an alternative categorization, excluding the fatigue subscale to check 
the impact of common physical complaints. 93% of the women were categorized similarly 
(r=0.88). 
Depressive symptomatology
The severity of the psychopathology was assessment by the self-rated Edinburg Depression 
Scale (EDS) and clinician-rated Hamilton Depression Rating Scale (HDRS) at baseline 
and at 6 weeks postpartum during a home-visit interview. The EDS is a 10-item self-report 
questionnaire that is validated to measure depressive and anxiety symptoms during pregnancy 
and in the postpartum period (score range: 0-30). A score of <13 represents no clinical relevant 
symptoms and a score above ≥13 justifies treatment [8]. The HDRS was added as a clinician-
rated scale to assess depressive symptoms based on 17-items (score range: 0-52) [9]. 
Data analysis 
Differences of the demographic and clinical characteristics and pregnancy outcomes across 
the mood phenotypes were tested with Chi Square test or Fisher Exact Test for categorical 
data, and ANOVA for normally distributed continuous data. We did not correct for multiple 
testing. Correlations between variables were calculated using Pearson (continuous variables) 
or Spearman’s rank (categorical variables) correlation tests. Missing data analyses showed 
that 6% was missing, distributed over 14 cases. MAR and MNAR was explored. We found 
no indication that missing variables were not distributed at random. Normality of the data was 
checked visually using histograms, and Q-Q plots. 
resulTs
From our clinical convenience sample of 99 pregnant women with a mental disorder, we 
identified three equally sized phenotypes based on their Total Mood Disturbance-score of the 
Profile of Mood States (POMS) across pregnancy: 
 I. Women that experienced severe mood fluctuations, eg. highly variable mood
 II. Women with a stable negative mood 
 III. Women with a stable positive mood
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Women with a fluctuating mood experienced feelings of depression, tension, anger, fatigue 
and a reduced vigour. The women with a stable negative mood experienced more severe 
feelings on all subscales. Stable positive women did not experience these feelings. All mean 
scores of the subscales and the Total Mood Disturbance (TMD) are depicted for the three 
phenotypes in Figure 1.
Figure 1 – Graphic presentation of three phenotypes of mood fluctuations across pregnancy (severe 
mood fluctuations variable, stable negative and stable positive mood) with mean POMS scores and error 
bars
The demographic and clinical characteristics are shown in Table 1. We found no differences 
between the three phenotypes. Mostly depressive and anxiety disorder were diagnosed in this 
sample, and more than half of the participants had a personality disorder. The phenotype with 
mood fluctuations included most cluster B personality disorders, but this was not statistically 
significant. At baseline, the mood scores across pregnancy according to the self-rated 
Edinburgh Depression Scale (EDS) and clinician-rated Hamilton Depression Rating Scale 
(HDRS) were significantly different between the three phenotypes, as expected from the 
POMS-scores. Women in the stable positive mood phenotype scored below the cut-off score 
of non-clinical relevant symptoms, and used a reference group. 
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Table 1 - Demographic and clinical characteristics of 99 participants
Mood phenotypes
p-value
Mood fluctuations
(n=33)
Stable negative
(n=33)
Stable positive
(n=33)
Demographic characteristics
Maternal age in years (m;sd) 29.4 (5.0) 31.8 (4.6) 31.1 (4.9) 0.11*
Planned pregnancy 22 (67%) 16 (49%) 22 (67%) 0.22
Marital status (N;%) 0.63
 Married/co-habiting 25 (76%) 28 (85%) 27 (82%)
Ethnicity 0.14
 Caucasian 25 (76%) 24 (73%) 30 (91%)
Educational level 0.29
 Low educational level 9 (27%) 11 (33%) 15 (46%)
Employment status 0.32
 Unemployed 24 (73%) 19 (58%) 24 (73%)
Clinical characteristics
Axis 1 Psychiatric disorder 0.07
          Depressive disorder 15 (46%) 17 (52%) 11 (33%)
           Anxiety disorder 10 (30%) 12 (36%) 10 (30%)
           Psychotic disorders - - 4 (12%)
 Other 1 (3%) 3 (12%) 3 (9%)
 No Axis 1 disorder 7 (21%) 1 (3%) 5 (15%)
Axis 2 Personality disorder 0.10
 Cluster A - 2 (6%) -
 Cluster B 16 (49%) 8 (25%) 9 (27%)
 Cluster C 3 (9%) 7 (22%) 3 (9%)
 No Axis 2 disorder 14 (42%) 15 (47%) 21 (64%)
Previous episode of anxiety/depression 0.08
 1 episode 5 (15%) 15 (46%) 10 (30%)
 ≥ 2 episodes 18 (55%) 14 (42%) 14 (42%)
 None 10 (30%) 4 (12%) 9 (27%)
Psychotropic medication use 0.13
 SSRI/nSSRI/TCA 13 (41%) 7 (21%) 10 (31%)
 Antipsychotics - 1 (3%) 2 (6%)
 Lithium 1 (3%) - 1 (3%)
 Benzodiazepines 1 (3%) - -
 Other 1 (3%) 1 (3%) -
 None 16 (50%) 24 (73%) 19 (59%)
Treatment in pregnancy
 Individual counseling 10 (30.3) 19 (57.6) 14 (42.4) 0.10
 Multicomponent 23 (69.7) 14 (42.4) 19 (57.6)
Any smoking in pregnancy 12 (36%) 10 (30%) 11 (33%) 0.96
Any alcohol in pregnancy 6 (18%) 11 (33%) 12 (36%) 0.22
Any illicit drug use in pregnancy 5 (16%) 1 (3%) 3 (9%) 0.06
Depressive symptomatology Mean (SD) Mean (SD) Mean (SD)
Edinburgh Depression Scale 15.3 (6.4) 17.6 (6.1) 8.7 (5.8) <0.001*
Hamilton Depression Rating Scale 11.4 (5.0) 14.1 (4.8) 6.5 (4.2) <0.001*
Note:
* All categorical variables were tested using Chi2-test, except for this variable Fisher Exact test is used.
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Table 2 showed the obstetric outcomes for the three phenotypes. A lower birth weight was 
more common in the severe mood fluctuation phenotype than in the stable negative or positive 
mood phenotypes. The number of SGA children did not differ between the three phenotypes. 
Postpartum complications were more observed in the mood fluctuation phenotype. 
Table 2 - Obstetric outcomes
Mood phenotypes p-value
Mood fluctuations
(n=33)
Stable negative
(n=33)
Stable positive
(n=33)
Perinatal complications (N;%)* 18 (56.3) 15 (48.4) 11 (35.5) 0.25
   Fetal distress (N;%) 5 (16.1) 8 (27.6) 7 (22.6) 0.56
Mode of delivery 0.95
   Spontaneous 22 (68.7) 23 (74.2) 21 (67.7)
   Instrumental 5 (15.6) 5 (16.1) 5 (16.1)
   Caesarean section 5 (15.6) 3 (9.7) 5 (16.1)
Gestational age (m;sd) 38.6 (1.9) 39.1 (2.2) 39.4 (1.8) 0.23#
   Premature birth <37wks (N;%) 5 (15.6) 3 (9.7) 1 (3.2) 0.25
Birth weight in grams (m;sd)** 3112 (508) 3477 (516) 3448 (492) 0.01#
   SGA <10 (N;%) 3 (9.4) 3 (9.4) 3 (9.4) >0.99#
Postpartum complication (N;%)*** 11 (34.4) 4 (14.8) 3 (10.3) 0.05
Pain relief (N;%) 24 (75.0) 21 (67.7) 20 (64.5) 0.65
Gestational diabetes 3 (9.4) 2 (6.7) 1 (3.2) 0.78#
Pre-eclampsia 1 (3.1) 0 (-) 1 (3.1) 0.99#
Hypertension 2 (6.2) 0 (-) 2 (6.5) 0.54#
Note:
In total 6% of outcome data was missing, distributed over 14 cases. Cases were distributed evenly over the 
clusters.
* Perinatal complications were grouped as: gestational diabetes, pre-eclampsia, pregnancy-induced hypertension, 
hospitalization >24 hour or suspected fetal distress (diagnosed on the basis of a pH < 7.2 on a fetal blood sample 
during delivery or Apgar score <7 after 5 minutes) 
** Birth weight obtained from obstetric records (recorded in grams); small-for-gestational-age (SGA) determined 
using birth weight adjusted for gestational age, parity and fetal gender. 
*** Postpartum complications included hospital admission, at 6 weeks postpartum women were asked whether 
the patient or baby had been hospitalized in the first 6 weeks after delivery
# All categorical variables were tested using Chi2-test, except for this variable Fisher Exact test is used. 
Table 3 shows the depressive symptoms as measured by the EDS and HDRS at 6 weeks 
postpartum. Both the self-rated as the clinician-rated depression scores were lower postpartum 
for the three phenotypes, compare to baseline. As expected, the stable positive phenotype 
scored below the cut-off scores for clinically relevant symptoms in the postpartum period. 
The mood fluctuations phenotype was subclinical depressed according to the clinician-rated 
HDRS.  
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Table 3 - Depressive symptomatology 6 weeks postpartum 
Mood fluctuations
(n=33)
Stable negative
(n=33)
Stable positive
(n=33)
p-value
Edinburgh Depression Scale (m;sd) 10.8 (6.7) 12.6 (5.5) 7.1 (4.8) 0.001
Hamilton Depression Rating Scale 
(m;sd)
6.4 (5.1) 8.6 (5.0) 3.6 (3.9) 0.001
Note: All variables were tested using ANOVA-test
discussion 
This pilot study describes in a sample of pregnant women with a mental disorder, a phenotype 
of severe mood fluctuations exists. This phenotype is also characterized by co-morbid 
psychiatric (e.g. more cluster B personality disorders) and psychosocial problems and we 
hypothesized that this might be related to poor pregnancy outcomes.
We identified three clinical relevant phenotypes based on their symptomatology, confirmed 
by depression rating questionnaires (EPDS/HDRS) at baseline and postpartum. We found 
that children of pregnant women with severe mood fluctuations - regardless of the underlying 
mental disorder - might have a lower birth weight within a normal range compared to those 
born to the women with a stable positive or negative mood. In line with this finding, the number 
of SGA babies was largest in the women with severe mood fluctuations, although this finding 
did not reach significance. Other obstetric outcome differences were not striking. Also more 
postpartum complications were observed in women with severe mood fluctuations. In this 
pilot study, the high variability of mood across pregnancy was associated with postpartum 
depressive symptomatology according to the Edinburgh (self-rated) depression scale (EDS) 
or clinician-rated Hamilton Depression Rating Scale (HDRS). 
Up to date, we know that untreated or incompletely managed depression increases the risk 
of postpartum depression, but may also adversely impair obstetric and birth outcomes [10]. 
Some studies reported that maternal psychopathology is negatively related to birth weight 
[11-14], Other studies observed no (independent) relation between maternal psychopathology 
and low birth weight [15-18]. It has been hypothesized that exposure to elevated intrauterine 
cortisol levels makes the HPA-axis of the child already susceptible to programming during fetal 
life, which places children at risk intra-uterine and for developing other problems in later life 
[19-21]. However, the level of maternal psychopathology and mood fluctuations will be likely 
influenced by the mental disorder, psychiatric co-morbidity and several psychosocial factors, 
like financial problems, marital conflicts, lack of social support, and stressful life events. 
Maternal psychopathology could also lead indirectly to reduced self-care, less obstetric 
checks, reduced food intake or by a low intake of essential fatty acids or vitamins, such as 
folic acid or vitamin B6 and B12 [22]. Next to these co-morbid psychiatric and psychosocial 
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problems, there are also protecting factors and the promising effect of psychotropic treatment 
or/and non-pharmacological interventions for mother and the unborn child. 
We hypothesized that one-time screening for maternal psychopathology in antenatal care 
could lead to an underestimation of the psychopathology due to mood fluctuations. The 
strength of this pilot study is that we collected a large number of repeatedly measurements of 
mood states in pregnant women with a mental disorder. We observed subclinical depression 
scores postpartum for the fluctuating mood phenotype, so severe mood fluctuations across 
pregnancy might not increase the risk of a postpartum depression.
This exploratory study suggests more studies with repeated measurements of mood states 
across pregnancy in order to investigate any additional risks for the mother and the unborn 
child due to severe mood fluctuations. Experienced sampling methods [23], for example by 
using an app on a smartphone would be non-invasive, relatively cheap and practical. Ideally 
one would like to examine mood and mood fluctuations across all trimesters because of 
embryogenesis and pregnancy outcomes, but it is difficult to engage women already in the 
first trimester. Also adjustment of pregnancy outcomes for clinical variables and correction for 
multiple testing would be recommended for future studies. 
From this hypothesis forming study, we conclude that in a clinical sample of pregnant women 
with a mental disorder a phenotype of severe mood fluctuations exists and this may affect 
the prognosis for mother and the unborn child. Our hypothesis that a fluctuating mood across 
pregnancy has an adverse impact on pregnancy outcomes should be tested in larger studies 
using repeated measurement of mood states, in order to further optimize screening, treatment 
and prognosis of maternal psychopathology.
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aBsTracT 
Women with severe mental illness are at increased risk of suicide in the perinatal period, 
and these suicides are often preceded by self-harm, but little is known about self-harm and 
its correlates in this population. This study aimed to investigate the prevalence of suicidal 
ideation and self-harm, and its correlates, in women with psychotic disorders and bipolar 
disorder during pregnancy. Historical cohort study using de-identified secondary mental 
healthcare records linked with national maternity data. Women pregnant from 2007 to 2011, 
with ICD-10 diagnoses of schizophrenia and related disorders, bipolar disorder or other 
affective psychoses were identified. Data were extracted from structured fields, natural 
language processing applications and free text. Logistic regression was used to examine the 
correlates of self-harm in pregnancy. Of 420 women, 103 (24.5%) had a record of suicidal 
ideation during the first index pregnancy, with self-harm recorded in 33 (7.9%). Self-harm 
was independently associated with younger age (adjusted odds ratio (aOR) 0.91, 95% CI 
0.85–0.98), self-harm in the previous 2 years (aOR 2.55; 1.05–6.50) and smoking (aOR 3.64; 
1.30–10.19). A higher prevalence of self-harm was observed in women with non-affective 
psychosis, those who discontinued or switched medication and in women on no medication 
at the start of pregnancy, but these findings were not statistically significant in multivariable 
analyses. Suicidal thoughts and self-harm occur in a significant proportion of pregnant women 
with severe mental illness, particularly younger women and those with a history of self-harm; 
these women need particularly close monitoring for suicidality.
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Background
The perinatal period is generally a time of both lower suicide risk [1, 2] and lower self-
harm risk [3, 4], but for women with severe mental disorders (SMI), the risk of suicide is 
increased up to 70-fold in women admitted for postpartum psychiatric disorders [5]. The UK 
Confidential Enquiries into Maternal Deaths and other studies have highlighted mental illness 
as a significant contributor to maternal deaths and also highlight a history of self-harm in a 
significant proportion (25–50%) of maternal suicides [6]. Compared with the postnatal period, 
women who die by suicide during pregnancy are reported more likely to have a diagnosis of 
schizophrenia/related disorders or of bipolar disorder and less likely to have a diagnosis of 
depression [7]. 
Little is known about the prevalence and risk factors of self-harm in pregnant women with 
severe mental disorders even though self-harm in pregnancy is potentially harmful to the 
viability of the pregnancy in addition to being a potential risk factor for suicide. Risk factors 
for self-harm in the general population include a history of self-harm [8], younger age [9], 
substance misuse [10], domestic and sexual violence [11], genetic risk [12] and severity of 
illness [13]. In addition, in pregnancy, a recent study [14] showed younger age and depression 
diagnoses were risk factors for suicidal behaviour-related hospitalisations in pregnant women 
but did not look at other mental health diagnoses. Illness severity and relapse have been 
associated with discontinuation of medication in one small study in women with bipolar 
disorder [15], but associations with risk of self-harm remain under-investigated.
We therefore aimed to investigate the prevalence of suicidal ideation and self-harm in pregnant 
women with SMI (schizophrenia/related disorders, bipolar disorder and other affective 
psychoses). We hypothesised that self-harm would be associated with markers of illness 
severity (non-affective diagnosis, substance misuse, smoking, a recent history of self-harm, 
recent hospitalisation), younger age, discontinuation or switching of regular maintenance 
psychotropic medication and recent domestic violence.
meThods 
Study design and data source
Historical cohort study uses de-identified electronic health records. Pregnant women with SMI 
were identified using the South London and Maudsley (SLaM) NIHR Biomedical Research 
Centre Clinical Record Interactive Search (CRIS) system [16]. This is a “new generation” of 
case register design, built on full electronic clinical records and allowing in-depth secondary 
analysis of both numerical, string and free-text data, while preserving anonymity through 
technical and procedural safeguards [17]. It is a rich source of prospective clinical data. SLaM 
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provides near-monopoly mental healthcare for a geographic catchment of around 1.2 million 
residents across four London boroughs, as well as specialist services. CRIS was approved 
as a source of the secondary data for research by Oxfordshire Research Ethics Committee C 
(08/H0606/71+5).
Fully electronic health records have been maintained since 2006, and at the time of data 
extraction, over 200,000 individuals had received care from SLaM. Several natural language 
processing applications have been developed for CRIS using General Architecture for Text 
Engineering (GATE) software in collaboration with Sheffield University [18]. Such applications 
derive structured data from free-text fields. As part of CRIS development, a data linkage 
service has been set up to link CRIS with other sources of secondary data, including Hospital 
Episode Statistics (HES) which provide national statistical data for all treatment in National 
Health Service hospitals in England, and includes maternity data.
Study population
This study is part of a larger programme of research on a cohort of pregnant women with SMI, 
described in detail previously [19]. The cohort includes all pregnant women with a diagnosis of 
schizophrenia and other non-affective psychoses, bipolar disorder, other affective psychoses 
including psychotic depression or previous puerperal psychosis (ICD-10 F20, F22, F23, F25, 
F28, F29, F30, F31, F32.3, F33.3 and F53.1), receiving SLaM care between 2007 and 2011. 
We excluded women with no SLaM clinical data during pregnancy. Structured fields and a 
GATE software application were used to extract the diagnosis nearest to the beginning of 
pregnancy.
Measures
We used a free-text search for records of suicidal ideation (SI) and self-harm during the first 
index pregnancy occurring in the study cohort. Self-harm was defined as a suicide attempt 
or self-injurious behaviour, including cutting, burning, hitting, hanging, overdosing, poisoning 
and electrocuting using terms validated in another CRIS study on self-harm and Emergency 
Department attendances [20]. Complete notes on the self-harm event were scanned for 
further information on the method of self-harm, triggers (reported hallucinations around 24h 
of the event, alcohol and substance use within 12h of the event) and location (whether event 
occurred on an inpatient ward or at home and whether the patient was under intensive Home 
Treatment).
Some socio-demographic variables were extracted from structured fields (age, ethnicity) 
and others from free text (partner status in index pregnancy). Free-text searches were also 
used for domestic violence before and/or during pregnancy and a history of child abuse. 
Smoking, alcohol and substance abuse during pregnancy were extracted using free-text 
searches and/or recent diagnosis of an alcohol or substance use disorder. Measures of illness 
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nature/severity were affective/non-affective SMI diagnosis at the beginning of pregnancy, 
self-harm and admissions to acute care in the previous 2 years. The highest total Health of 
the Nation Outcome Scale (HoNOS) score in the 2 years before pregnancy was extracted 
to approximate baseline level of functioning. HoNOS, a structured instrument, is a 12-item 
measure of health and social functioning of people with severe mental illness, routinely 
collected in UK mental health services; scores above 10 indicate poor functioning and are 
generally recorded in inpatients [21]. Information on acute admissions (including inpatient 
and intensive Home Treatment) was extracted from CRIS and HES [19]. Home Treatment 
Teams are a national network of teams providing intensive community-based support as 
an alternative to hospital admission for acutely unwell patients [22]. Regular psychotropic 
medication use (antidepressants, mood stabilisers or antipsychotics) and changes in the first 
trimester were also extracted: psychotropic drug names and changes in regular use of these 
medication groups during first trimester were extracted using GATE software to guide retrieval 
of clinical text [19]. Where no drugs were identified, a free-text search for “medication” was 
used, and where it was not possible to establish whether medication was being used or not in 
the first trimester, this was coded as “not known.” Regular maintenance medication in the first 
trimester was categorised into “stopped or switched a medication,” “continued a medication” 
and “no medication at the beginning of pregnancy.” “Non-adherence” was coded if there was 
a comment in the notes regarding concern about adherence indicating the possibility of no 
exposure to a given medication in the first trimester. For self-harm and medication changes 
occurring in the first trimester, we checked the notes manually to ascertain which happened 
first: the self-harm or the medication change.
Data-analysis
We used Stata version 12 [23]. Independent-sample T tests and Mann-Witney tests (for 
continuous data) and Pearson’s chi-square (for categorical data) were used to compare 
demographic and clinical characteristics between women with or without a record of self-harm 
during pregnancy. Cells containing n < 5 were not reported to maintain anonymity of the data. 
Cases with missing information on presence of a partner, reported abuse, substance misuse, 
current smoking and self-harm history were assumed to indicate that these were not present. 
Inter-rater agreement on self-harm data was assessed for the first 10 records and for a 10% 
random sample; two raters agreed on 89% of the data and consensus meetings resolved 
discrepancies; detailed guidance on how to code data was used for subsequent data coding.
Multivariable logistic regression analysis using cases with known medication status was 
performed to examine the correlates of self-harm during pregnancy. We compared these 
women with those with missing medication status on age, ethnicity, baseline diagnosis and 
acute admissions (variables in the multivariable analysis that did not depend solely on clinical 
text). HoNOS was not entered into the multivariable model, as data were only available for 
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236 of 420 women. We conducted a sensitivity analysis excluding women who had a self-
harm event before a medication change in the first trimester in order to address the potential 
issue of reverse causality. We also conducted sensitivity analyses using women who stopped 
medication only compared with continuers and excluding women reported as non-adherent 
to medication. Selection was based on our a priori variables and those with p ≤ 0.2 in the 
bivariate analysis. All hypothesis testing was two-tailed with Į set to 0.05.
resulTs 
Our study population consisted of 420 women. Of these, 40 women had pregnancies which 
ended in the first trimester and 10 in the second. HoNOS scores were available for 236 women 
only, and 413 women had data on medication status in the first index pregnancy. There was 
no other missing data on covariates.
Prevalence of suicidal ideation and self-harm in the index pregnancy, n = 420 women
For 103 (24.5%) women, there was a report of suicidal ideation during the index pregnancy, 
while 178 (42.4%) women denied this; in the remaining 139 (33.1%) women, there was no 
mention of suicidal ideation or self-harm. For 70 (16.7%) women, there was a report of suicidal 
ideation but there was no event of self-harm reported during the pregnancy. Of the 420 women 
in the study, 33 (7.9%) had a self-harm event during their index pregnancy, and 9 of these had 
multiple events (range 1–7); 15 women had a self-harm event in the first trimester, 16 in the 
second trimester and 10 in the third.
Self-harm by event, n = 52 events
In total, 52 events of self-harm (but no suicides) were reported in 33 women out of 420 (1 
event per 19 pregnancies). Of the 52 events, methods of self-harm were overdoses (n = 20, 
38.5 %), hitting (n = 12, 23.1%), cutting (n = 9, 17.3%) or using a violent method (n = 11, 21.2%) 
such as jumping from height, burning or hanging. Of 52 self-harm events, 23 (43.1%) occurred 
while women experienced hallucinations. In 18 out of 52 (34.6%) events, drugs or alcohol 
were involved within 12h before the self-harm. The majority of self-harm events took place at 
home (n = 38, 73.1%) compared with an inpatient setting (n = 14, 26.9%). Of events that took 
place at home (n = 43), 13 (30.2) were carried out while the woman was under intensive Home 
Treatment care.
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Factors associated with self-harm during the index pregnancy, n = 420 women
All women with self-harm in the first index pregnancy also reported suicidal ideation in 
pregnancy. Self-harm in pregnancy was associated with younger age, a history of child abuse 
or domestic violence, current (i.e. during pregnancy) domestic violence, a history of self-harm 
in the 2 years preceding pregnancy, substance misuse, smoking, non-affective disorder, 
acute admissions in the 2 years preceding pregnancy and stopping or switching rather than 
continuing a maintenance medication in the first trimester of pregnancy (Table 1)
For multivariable analyses, 7 women were excluded as their medication status in the first 
trimester of pregnancy was not known. Therefore, 413 women were included, 33 (8.0%) of 
whom had a self-harm event in their index pregnancy. Suicidal ideation was not included in 
the analyses due to perfect prediction. There were no differences in age (t = −0.21, p = 0.833), 
ethnicity (chi2 = 4.53, p = 0.104), diagnosis (chi2 = 1.59, p = 0.208) and admission rate 
(chi2 = 0.00, p = 1.000) between those who were included and not included in the multivariable 
analyses.
In the fully adjusted models (Table 2), there was evidence of associations between self-harm 
in pregnancy and younger age, smoking and a recent history of self-harm and the adjusted 
odds ratio for discontinuation or change in maintenance medication compared with continuing 
medication was attenuated by around 50% and no longer significant.
Fewer than five women had a medication change after the self-harm event. Sensitivity analysis 
excluding these women led to a further attenuation of the relationship between medication 
changes and self-harm (Table 2), and the association with history of self-harm was no longer 
significant. Non-affective diagnosis appeared to be associated with self-harm, but this did 
not quite reach statistical significance (p = 0.055). Other sensitivity analyses did not lead to 
substantial differences (see Table 2).
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discussion
This is the first study, to our knowledge, to report on the prevalence of self-harm in pregnant 
women with severe mental illness, a group already recognised to be at increased risk of 
maternal suicide. We found that 25 of this cohort had recorded suicidal ideation in pregnancy, 
a similar rate to that reported in a clinical population of 360 pregnant women referred to a 
perinatal mental health programme with lifetime history of DSM Axis I mental disorder [24]. 
Of particular, clinical concern was our finding of self-harm in 8%, with violent methods used 
in a fifth, indicating potential severity of intent and illness which has been found in studies of 
suicide in general populations [25] and perinatal suicides [7]. We confirmed our hypotheses 
that self-harm was associated with illness severity - smoking, and previous self-harm and, 
though weaker evidence, non-affective diagnosis.
Medication discontinuation was not significantly associated with self-harm, though this may 
reflect a lack of statistical power. In pregnancy, clinicians as well as patients may be concerned 
to avoid medication due to concerns about teratogenicity, particularly in the first trimester, and 
we have described elsewhere that 78.6% of those who stopped medication in this cohort 
were indeed recorded as stopping “because of the pregnancy” [19]. Recent systematic 
reviews and well-designed cohort studies suggest that the small increased risk of congenital 
malformations in this population appears to be due to confounding factors, [26, 27] other than 
for some mood stabilisers, particularly valproate [28]. While this study cannot confirm whether 
or not medication changes in pregnancy could lead to self-harm, there are likely to be complex 
relationships between illness severity, medication change and self-harming behaviour that 
are not easy to disentangle in observational research. Screening and close monitoring is 
therefore essential for pregnant women with SMI, particularly those with markers of severity 
who discontinue medication, in order to prevent repetition of self-harm [9].
Finally, it was noteworthy that this population had high prevalence of substance misuse, 
smoking and reported domestic abuse - all risk factors for adverse foetal outcomes which 
need to be addressed by maternity and mental health professionals [29].
Strengths and limitations
Strengths of the study include the use of data from a large representative sample of pregnant 
women with SMI observed longitudinally within a comprehensive clinical database. The unique 
features of the data source enabled us to access data on a group who are a particularly hard-to-
reach population to recruit into clinical studies [30]. Other studies looking at self-harm, suicide 
and suicidal ideation in pregnancy have often excluded patients with SMI; utilising these 
clinical records enabled us to capture a group of women who are potentially at particular risk 
and yet are under-represented in research, particularly women with schizophrenia. The use 
of Hospital Episode Statistics provided a robust method of identifying pregnancies regardless 
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of hospital of birth. It did not include home births, which account for about 2.4% of births for 
England in 2011 [31]; however, as women with SMI are high-risk pregnancies, it is unlikely 
that many deliver at home. Hospital Episode Statistics also enabled us to collect information 
on admission histories covering the whole of England for this potentially mobile population. An 
additional strength was the detailed information on psychotropic medication use, in addition to 
histories of abuse and other exposures usually not available in administrative datasets.
Limitations include the use of information recorded by clinical staff, which could underestimate 
suicidal ideation and self-harm prevalence - women may not disclose suicidal thoughts or acts 
as they may be worried about custody loss [32, 33]. There was no mention of suicidal ideation 
in the notes for 33% of women, which may have been due to suboptimal record-keeping. 
Finally, we cannot assume generalizability to all women with SMI and pregnancy, as we did 
not include women with SMI managed solely in primary care.
conclusions 
The comparatively high level of suicidal ideation reported, and the significant levels of self-
harm recorded, indicates that women with SMI in pregnancy are a high-risk population who 
require close monitoring in pregnancy.
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general discussion 
The overall aim of this thesis was to extend the existing knowledge about the treatment 
and impact of mental disorders during pregnancy by evaluating a new group-based 
multicomponent therapy using a Randomized Controlled Trial (RCT). This therapy was based 
on clinical expertise and a systematic review of all interventions to treat mental disorders 
during pregnancy as described in Part I of this thesis. Part II explored the impact of having a 
mental disorder on sleep and mood fluctuations during pregnancy. In addition, the prevalence 
and correlates of suicidal ideation and self-harm were investigated in a cohort of pregnant 
women with psychotic disorders such as schizophrenia and bipolar disorders.
In the previous chapters, the main results, merits and shortcomings of the studies were 
discussed in detail. This chapter provides a general discussion of the main findings, 
methodological considerations, implications for further research and a final conclusion.
main findings of sTudies presenTed in This Thesis 
Part I Treatment of mental disorders during pregnancy
After reviewing all controlled studies on interventions for the treatment of a broad spectrum of 
mental disorders during pregnancy, we found no controlled studies on the effect of psychotropic 
medication. With respect to non-pharmacological treatment of the broad spectrum of mental 
disorders, we only found controlled studies focusing on depression. Therefore we could only 
estimate effect sizes for treatment of patients diagnosed with Major Depressive Disorder 
(MDD). In our meta-analysis psychotherapy for MDD showed robust effect sizes, in particular 
Cognitive Behavioural Therapy (CBT, g=-0.61), and to a lesser extent Interpersonal Therapy 
(IPT, g=-0.67). This is in line with current NICE guidelines that advise clinicians to offer a 
form of psychotherapy to every pregnant woman with a current or history of mild to severe 
depression [1].
Based on the clinical experience of our perinatal mental health team and relying on 
evidence-based components from other treatments during pregnancy, a new Group-based 
Multicomponent Treatment (GMT) was composed for pregnant women with co-morbid 
psychiatric and psychosocial problems. GMT aimed at the reduction of stress, depressive 
and anxiety symptoms, and has a special focus on emotional and practical preparation for 
motherhood. An RCT – the DAPPER-trial – evaluated this weekly one-day GMT compared to 
individual counselling (Treatment As Usual) for the reduction of depressive symptoms during 
pregnancy. DAPPER is an acronym for Daycare Alternative Psychiatric Pregnant women 
Efficiency Research. Our study showed that GMT is a feasible and well-accepted treatment 
for a clinical sample of pregnant women with co-morbid and diverse psychiatric disorders 
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(e.g. anxiety disorders and personality disorders) and psychosocial problems. We observed a 
reduction of depressive symptoms during treatment, but we could not demonstrate that GMT 
is more effective than individual counselling. It might be that our control arm depicts the effect 
of individual counselling and/or the natural course of symptoms, leading to regression to the 
mean. We expected that depressive scores would be the same or lower in the postpartum 
period, based on cohort studies measuring depression across pregnancy and the postpartum 
period [2, 3]. Given the lack of evidence for superiority of any specific therapy, clinicians 
should consider and discuss different treatment options. I would recommend a form of CBT, 
but also taking into account personal circumstances and preferences of the patient. There 
were no differences on treatment outcomes or drop-out rates between women who were 
randomized or choose their treatment of preference (GMT or TAU). The literature shows that a 
tailored treatment advice enhances engagement and compliance of the patient, which is likely 
to increase the effect of the treatment.
Part II Impact of a mental disorder during pregnancy
Mental disorder and sleep during pregnancy
During pregnancy, symptoms of a mental disorder (e.g. MDD and anxiety disorders) affecting 
mood, sleep, appetite and energy are often difficult to distinguish from the normal experiences 
of pregnancy. We explored the impact of a broad spectrum of mental disorders on sleep quality 
and measured it subjectively by a daily sleep diary and objectively by an Actiwatch in a case-
control study. A mental disorder during pregnancy is associated with poorer subjective sleep 
quality but not with worse objective sleep quality. This result demonstrates the importance 
of focusing on the perception of sleep in pregnant women with a mental disorder who report 
sleep problems. It is worth noting that most pregnant women – with and without mental 
disorder – had a suboptimal subjective and objective sleep quality. This was measured with 
the Pittsburg Sleep Quality Inventory (PSQI), which is a measure for sleep quality, and with 
actigraphy, which is an objective measure to determine sleep characteristics.
Mental disorder and mood fluctuations
Poor sleep quality influences mood, and vice versa. In another study we described three 
phenotypes of mood fluctuations in women with a mental disorder across pregnancy. Based 
on the weekly Profile of Mood State, we identified three phenotypes: severe mood fluctuations 
(highly variable), stable negative (more depressed/anxious) and stable positive mood. We 
observed no differences between the three phenotypes based on demographics, clinical or 
pregnancy outcomes, except for a lower birth weight in the fluctuating mood phenotype. In this 
clinical sample, there is a substantial group with severe mood fluctuations. This phenotype is 
also characterized by co-morbid psychiatric and psychosocial problems and we hypothesized 
that this fluctuating mood phenotype might be at risk for poor pregnancy outcomes. Although 
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these findings are interesting, they need to be replicated in a larger sample to further 
understand the underlying mechanisms and using repeated measurements of mood state.  
Mental disorder and self-harm during pregnancy
In case of severe mood fluctuations, a clinical concern is suicidal ideation and self-harm. We 
studied the prevalence of self-harm in a group at increased risk of maternal suicide, i.e. a 
unique cohort of pregnant women with schizophrenia/related disorders and bipolar disorder 
from a ‘new generation’ case register (CRIS) in London. Out of the 420 women in the study, 
25% recorded suicidal ideation and 8% had a self-harm event during their pregnancy, with 
violent methods used in a fifth. We confirmed our hypotheses that self-harm was associated 
with illness severity - smoking, and previous self-harm, and to a lesser extent with a non-
affective psychiatric diagnosis.
meThodological consideraTions
All studies included in this thesis were embedded in the DAPPER-trial, except for one study. 
In this paragraph we will discuss the strengths and limitations of the DAPPER-sample, study 
design and measurements. Hereinafter we will discuss the limitations of the cohort of pregnant 
women with a severe mental disorder from London. 
DAPPER cohort
A limitation of the DAPPER-trial was the relatively small number of participants (n=158) to 
test the efficacy of a Group-based Multicomponent Treatment. Compared to other studies 
in the field of perinatal psychiatry, this is still a substantial number since this is a hard-to-
reach and difficult to engage population. Affected women are sometimes overwhelmed with 
both emotional adaptation to – often unexpected or unwanted – pregnancy and other time 
and energy consuming aspects (e.g. perinatal visits, practical preparation for the baby, and 
relational, family and work related issues). Due to our design and incentives, 20 (11.2%) 
eligible women refused participation and almost two out of three women who were willing to 
participate consented to randomization. The drop-out during the study was remarkably low 
(9/155, 5.8%). Drop-out and non-compliance was not associated with patient characteristics, 
such as parity and gestational age. We chose a clinical sample from an outpatient clinic and 
deliberately included other mental disorders next to major depressive disorder (MDD). Besides 
MDD (46.2%), our sample existed of anxiety disorder (31.6%) and comorbid personality 
disorders (49.4%). We did this, as this heterogeneity of mental disorders reflects clinical 
practice. Thus this practice enhanced the generalizability of our studies to other outpatient’s 
clinics focusing on perinatal psychiatry. At the other hand, our GMT was not specially designed 
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for the treatment of a broader spectrum of mental disorders, including personality disorders 
or anxiety disorders. Our GMT was not supported by evidence-based literature, but is derived 
from effective treatments for MDD. The sensitivity analysis supported our main findings and 
most likely it was not the result of a certain subgroup. 
The DAPPER-trial was designed as a patient-preference RCT and therefore suitable to 
compare the treatment effect of GMT versus Treatment As Usual (TAU). Strength of the study 
design was that it allowed us to additionally investigate the effect of patient’s preference for 
group-based or individual therapy on treatment response [4]. Since there were no differences 
in baseline characteristics, compliance, drop-out or treatment outcomes between the 
randomized and patient-preference condition, also in this respect support our results the 
generalizability to clinical practice [5]. Depressive symptoms in both GMT and TAU group 
decreased until after delivery, our RCT did not show a significant difference in decrease of 
depressive symptoms between GMT and TAU. It could be a power issue due to our relatively 
small sample size. However, it is questionable whether a larger sample size had ensured 
an effect. We speculate it might be related to the effective control condition of TAU. The 
treatment as usual is offered in a specialized tertiary centre for perinatal mental disorders with 
experienced clinicians and this tailored treatment could be as effective as GMT. 
A set of questionnaires was used in the DAPPER-trial. The Edinburgh Postnatal Depression 
Scale (EPDS) was used during pregnancy and as a primary outcome at 6 weeks postpartum 
according prepublished protocol. EPDS is a self-report questionnaire validated to measure 
depressive and anxiety symptoms during pregnancy and postpartum [6]. We missed more 
than half of the 10 and 15 week follow-up assessments during pregnancy and this most 
certainly limited the ability of study to detect a treatment effect. Generalized mixed model 
analysis is robust for missing values, but it cannot undo the effect of power loss due to the 
small sample size. Our findings showed no differences in the Intention To Treat-analysis and 
Per Protocol analysis. Possibly, the treatment effect during pregnancy was faded away after 6 
weeks after giving birth and additional life-events.
Next to the EPDS, we also assessed depressive symptoms by the Hamilton Depression 
Rating Scale (HDRS) [7]. HDRS is a clinician-rated scale; unfortunately the assessor was not 
blinded for the treatment condition and there could possibly be information bias. It was also 
not possible to blind participants because of the overt treatment conditions. 
Since we did not investigate other potential benefits of GMT above TAU, like improvement of 
lifestyle, social support or maternal mentalization capacity or bonding to the unborn child, we 
cannot exclude that women improved on other domains. 
Although one third of the DAPPER-sample was diagnosed with an anxiety related disorder, 
we did not assess anxiety symptoms during pregnancy or used it as an outcome. 
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Cohort from London
From the literature we know that those women, who die by suicide during pregnancy, are 
more likely to have a diagnosis of schizophrenia related disorders or bipolar disorder and less 
likely to have a diagnosis of depression. Due to a very small number of these diagnoses in 
our DAPPER-sample, we decided to cooperate with the Section of Women’s Mental Health of 
the Institute of Psychiatry of King’s College London. As a result of this collaboration, we had 
access to data from a large representative sample of pregnant women with a severe mental 
disorder observed longitudinally within a comprehensive clinical database (CRIS). Other 
studies looking at self-harm, suicide and suicidal ideation in pregnancy have often excluded 
patients with a severe mental disorder. Utilizing these clinical records enabled us to study 
a group of women, who are potentially at particular risk, and yet are underrepresented in 
research, particularly women with schizophrenia.
A possible limitation by using information recorded by clinical staff on a sensitive topic, we 
might have underestimated suicidal ideation and self-harm prevalence. In other words, women 
may not disclose suicidal thoughts or acts, as they may be worried about custody loss. There 
was no mention of suicidal ideation in the records for 33% of women, which may have been 
due to suboptimal recordkeeping.
implicaTions of currenT findings and proposed fuTure research 
As mentioned in the Introduction and confirmed in our meta-analysis, we highlight the fact that 
the treatment of a broader spectrum of mental disorders during pregnancy is not represented 
in current research. While anxiety, bipolar and other psychotic disorders may adversely affect 
mother and unborn child too, next to depression, we strongly recommend further research on 
both pharmacological and non-pharmacological treatment options for each specific mental 
disorder during pregnancy. 
Our well-designed RCT for a clinical sample did not show a significant difference in decrease 
of depressive symptoms between CBT-based GMT and treatment as usual (TAU = individual 
counselling). Also in our meta-analysis we found that the effect sizes of the different 
psychotherapies (CBT and IPT) are close to each other and possibly redeemable. It could 
be the case that it is not really important what kind of psychotherapy (CBT, IPT, GMT, or 
individual counselling) a patient is offered, as long as the patient is motivated for the treatment 
and being closely monitored by a specialised perinatal mental health care professional. It 
does not necessary mean, if more therapy components are offered that this will result in a 
more effective or beneficial treatment. An option would be to include a control condition in a 
trial, for example a ‘waiting list’-condition. However, we are aware of the ethical concerns in 
this design, i.e. withholding treatment in women with an identified mental disorder. Another 
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challenge would be to formulate other treatment or composite outcomes, which measure 
other potential additional benefits of the enhanced treatment, e.g. improvement of several 
life domains like 1) health, e.g. visiting antenatal care; 2) daily functioning; 3) partner and 
family relationships or 4) preparation for motherhood, for example by using the Experience of 
Motherhood Questionnaire [8]. 
Fortunately, the last couple of years there have been a growing awareness of the special need 
and treatment for pregnant women with a mental disorder. This has resulted in the foundation of 
several perinatal psychiatric outpatient clinics, the POP (Psychiatry Obstetrics Paediatricians) 
clinics in the Netherlands. In general, these different clinics offer a personalized treatment 
advice composed by professionals of the aforementioned three medical specialties and 
(referral to) tailored psychiatric care. Often a form of counselling or psychotherapy is offered, 
but there are local differences in available options. For the future, it would be interesting to 
evaluate (the cost-effectiveness of) these POP-clinics. However, this is a challenge because 
there are different reasons for referral, different local triage and treatment regimes for each 
POP-clinic. It is difficult to define a homogenous sample, to standardise an evidence-based 
treatment and to use a sensitive measurement method to monitor treatment outcome for 
mother and/or child. Furthermore, a cost-effectiveness analysis is challenging due to a 
broad spectrum of – psychiatric-related – health care costs, e.g. psychiatric specialized care, 
obstetric care, hospitalisation and other psychiatric and psychosocial outpatient care.  
Besides the evaluation of non-pharmacological interventions, there is a need for more 
controlled pharmacological trials because current evidence for the effectiveness and potential 
harm of psychotropic medication during pregnancy is based on naturalistic studies, case-
series and case-reports. For other designs, e.g. for example a discontinuation trials, there are 
ethical and methodological issues. Despite the lack of evidence, about 2% of the women in 
the Netherlands use Selective Serotonin Reuptake Inhibitors (SSRIs) during their pregnancy 
[9]. However, SSRI use during pregnancy is controversial because of unknown risk for the 
unborn child. While on the other hand relapse of depression during pregnancy holds also 
risks for both mother and child. One of the first multicentre RCT on the effect of continuation 
or guided tapering of SSRIs on both mother and child is recently started at our Departments 
of Psychiatry and Obstetrics and Gynaecology in close collaboration with the University of 
Utrecht and Groningen (www.stoporgostudie.nl). This study is promising but prospective 
controlled trials on other psychotropic medication are also necessary, e.g. SNRI’s, TCA’s, 
mood stabilizers and antipsychotics. Of paramount importance is the follow-up of children 
exposed to intrauterine psychotropic medication and to study the obstetric outcomes and 
long-term child neurodevelopment. 
Beyond the potential impact of the psychotropic medication, it would be very interesting to study 
the impact of intra-uterine stress related to maternal psychopathology on the fetus. A relatively 
new potential technique is to measure cortisol in hair as a biomarker of hypothalamic-pituitary-
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adrenocortical (HPA)-activity and prolonged stress during the past months. One study found 
a positive relation between perceived maternal stress and hair cortisol concentration (HCC) 
in healthy pregnant women [10], in contrast to Wikenius et al. who did not find a correlation 
between depression during pregnancy and HCC [11]. These results are preliminary and 
heterogeneous. For future research, it would be interesting to simultaneously investigate 
whether self-reported stress reduction in an intervention trial could be also objectivised in a 
reduction of cortisol in both mother’s and infant hair.  
As suggested by Glover, prenatal anxiety or depression may contribute 10-15% of the 
attributable load for emotional and behavioural outcomes of the child [12]. These adverse 
outcomes have a wide range, including emotional problems, impaired cognitive development 
and developing a mental disorder later in life [13]. There is only a small number of studies 
investigating the effect of a non-pharmacological intervention during pregnancy on the long-
term neurodevelopment of the child/adult. A small RCT in Australia showed that a brief 
CBT intervention reduced anxiety during pregnancy and improvements in depression in the 
postpartum period [14]. Nine-month infant outcomes showed several medium to large effects 
favouring the intervention in domains including problem solving, self-regulation and stress 
reactivity, which were independent of maternal postnatal mood. Other studies are still on-
going, like the ACORN study in the UK that offers a brief intervention to reduce maternal 
anxiety and studies infant temperament and sleep [15]. The Dutch PROMISES-trial showed 
no difference on maternal depressive symptoms after a CBT invention compare to treatment 
as usual, but there is no data available yet on the infants’ behavioural/emotional problems at 
1.5 years [16]. 
Next to depressive symptoms, there is an increasing interest to screen and treat (co-morbid) 
anxiety disorders during pregnancy. The State Trait Anxiety Inventory has been used in research 
with pregnant women but there are some issues of validity for the use during pregnancy [17]. 
In the literature, there are a few anxiety inventories, which are validated for the use during 
pregnancy. A validated questionnaire on general and pregnancy-specific anxiety symptoms 
is necessary to accurately screen for anxiety symptoms and to evaluate interventions [18], 
e.g. the Perinatal Anxiety Screening Scale (PASS) seems promising [19]. Moreover, the 
Pregnancy-Related Anxiety Questionnaire (PRAQ) is a robust predictor of birth-related and 
childhood outcomes, independent of general anxiety measures [20]. Recently the question 
about previous deliveries is changed, so the revised version (PRAQ-R) can be used in both 
nulliparous and parous pregnant women [21]. A specific form of anxiety during pregnancy is 
fear of childbirth – tocophobia - and the Wijma Delivery Expectancy Questionnaire (WDEQ) is 
validated for the use during pregnancy and in the postpartum period [22]. This questionnaire 
could be useful to detect PTSD after childbirth and evaluate future treatments, e.g. Eye 
Movement Desensitization and Reprocessing (EMDR) [23]. 
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In line with the above statements on the treatment of the full spectrum of mental disorders, 
future research should also focus on co-morbid psychiatric and psychosocial problems, 
like personality disorders, socio-economic status (SES), social support and life style. For 
example, our previous study focusing on the role of psychiatric and psychosocial problems 
on birth outcomes showed that low SES and the accumulative effects of psychiatric and 
psychosocial risk factors have a stronger impact on decreased birth weight and preterm birth 
above depressive symptoms [24]. For obstetric caregivers, it is important to systematically 
screen for psychosocial problems and substance use (for example through the validated 
Mind2Care instrument (7)) and to make sure that adequate and effective interventions will be 
offered and monitored. A Medical Social Worker can be of great added value to the perinatal 
treatment team of a psychiatrist, gynaecologist and paediatrician for case management. A local 
development is that a part of the treatment plan is executed in the neighbourhood, for example 
the program for vulnerable pregnant women in Rotterdam in close collaboration with Erasmus 
University Medical Centre called Mothers of Rotterdam (https://www.moedersvanrotterdam.
nl/). In the Netherlands, a municipal initiative called ‘VoorZorg’ for the care of pregnant women 
until the age of 25 (https://cjgrijnmond.nl/prenataal-aanbod-voorzorg) is being implemented. A 
new initiative would be providing ‘preparing for motherhood’ group classes under professional 
supervision (e.g. Centering Pregnancy groups [25]), also to promote social cohesion among 
the vulnerable pregnant women and to save travel costs. This could be in close collaboration 
of the perinatal team with the general practitioner, midwife, outreaching psychosocial support 
institutions and Center for Youth and Families. This has also advantages for the postpartum 
period, to closely monitoring child development, support-parenting skills and to discuss 
contraception in an early phase.  
final conclusions
- In our comprehensive systematic review, we could not find any controlled study for 
the treatment of mental disorders during pregnancy with psychotropic medication 
(e.g. antidepressants, antipsychotics and/or mood-stabilizers). Non-pharmacological 
trials, other than within pregnant women with a major depressive disorder (MDD), 
are scarce. We found a robust moderate treatment effect of Cognitive Behaviour 
Therapy (CBT) for MDD during pregnancy, and to a lesser extent for Interpersonal 
Psychotherapy (IPT). In line with the NICE guidelines, we advise a form of 
psychotherapy and therapies might be redeemable, depending on local availability 
and personal preference. 
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- Our Group-based Multicomponent Treatment (GMT) is an acceptable treatment for a 
heterogeneous group of pregnant women with depressive symptoms and co-morbid 
mental disorders and/or low SES, but not superior to treatment as usual.
- Our exploratory study on the quality of sleep in pregnant women with a mental 
disorder suggests that perceived sleep quality reported on a daily basis is worse 
than the sleep quality as measured by wrist actigraphy.
- We found a high level of suicidal ideation and significant levels of self-harm records 
among pregnant women with psychotic disorders and bipolar disorder, indicating that 
women with a severe mental disorder in pregnancy from a high-risk population that 
require close monitoring in pregnancy.
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summary 
The aim of this thesis is to extend existing knowledge on the treatment and impact of a 
mental disorder during pregnancy, more specifically on sleep quality and patterns of mood 
fluctuations and evaluating a new group-based multicomponent treatment. Chapter 1 provides 
a literature review of mental disorders during pregnancy and explains that a broader range 
of mental disorders and co-morbid mental disorders (e.g. anxiety disorders and personality 
disorders) is prevalent during pregnancy. This review applies to women who are previously 
diagnosed with a mental disorder, and those who experience psychiatric symptoms for the 
first time. According to prevalence rates varying from 3 to 11%, pregnancy seems to be neither 
protective nor exacerbating. The prevalence, symptoms and specific issues (e.g. course and 
concerns during pregnancy) related to pregnancy are not only discussed for Major Depressive 
Disorder (MDD), but also for bipolar disorder, anxiety related disorder, eating disorder and 
schizophrenia related disorders. Maternal psychopathology is related to increased intra-
uterine cortisol levels, as a result of maternal stress. This mechanism is associated with 
impaired fetal development, leading to a lower birth weight and premature birth and affects 
long-term infants development. Besides the direct influences, there are also indirect negative 
effects, like worse self-care and more substance abuse. Also sleep and mood fluctuations are 
often reported during pregnancy, but little is known on specific patterns of mood and whether 
sleep quality is objectively worse or the perception is altered. 
The challenge for the treatment of mental disorders during pregnancy is to balance between 
the deleterious effects of the disease and largely unknown effects - on the fetus - of 
pharmacotherapy. The NICE guidelines from the UK advise clinicians to do a risk-benefit 
analysis, to weigh the risk of relapse against the potential risk for the fetus and encourage 
the use of non-pharmacological interventions. Based on the findings from previous non-
pharmacological intervention studies and our clinical experience, a new group-based 
multicomponent therapy (GMT) was developed from other evidence-based group-based 
treatments for mood disorder. GMT aims to reduce stress, depressive and anxiety symptoms in 
pregnant women with a special focus on emotional and practical preparation for motherhood. 
This weekly open group therapy includes Cognitive Behavioural Therapy (CBT), psycho-
education, psychomotor therapy and relaxation therapy. An RCT, the DAPPER-trial evaluated 
GMT compared to individual counselling (treatment as usual, TAU) in reducing depressive 
symptoms in pregnant women with a mental disorder. After a structured diagnostic interview 
(SCID) and written informed consent, participants fulfilled 3 questionnaires on mood and 
sleep quality during pregnancy and the Edinburg Depression Scale at 6 weeks postpartum, 
which was used as primary outcome. 
Chapter 2 gives a systematic review of the literature of all available treatments for the broad 
spectrum of mental disorders in pregnant women. Until today, there are no controlled studies 
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on the effect of psychotropic medication for mental disorders during pregnancy. In our meta-
analysis we could only estimate treatment effect sizes for MDD due to a lack of studies on 
other disorders. Psychotherapy for MDD has robust effect sizes, e.g. CBT (g=-0.61), and 
less robust weighted-effect, Interpersonal Psychotherapy (IPT, g=-0.67). Both may hold 
potential benefit for pregnant women with MDD in this analysis. This is in line with current 
NICE guidelines that advise clinicians to offer a form of psychotherapy to every pregnant 
woman with a history of mild to severe depression and emphasizes close consultation with 
patients. Other potential effective non-pharmacological interventions to treat MDD were body-
oriented interventions and acupuncture. Bright light therapy is not associated with a decrease 
of depressive symptoms, but this is based on two trials with low sample sizes. The overall 
effect sizes of all non-pharmacological intervention are in close range to each other and may 
be redeemable for one other, bearing in mind the high attrition rates of most trials. Therefore 
we suggest that the preference of the patient have to weigh heavily in the decision for a 
psychiatric treatment in a clinical setting.
Chapter 3 describes the DAPPER-trial, the first RCT among a clinical sample of pregnant 
women with co-morbid psychiatric and psychosocial problems, evaluating a new group-based 
multicomponent therapy to reduce depressive symptoms during pregnancy. Overall, there 
was no significant difference observed in decrease of depressive symptoms between GMT 
and treatment as usual (TAU) at 6 weeks postpartum. We were able to successfully recruit 
a hard-to-reach population (n=158); only 20 (11.2%) eligible women refused participation, 
almost two out of three women willing to participate consented to randomization and drop-out 
was low (9/155, 5.8%). We diagnosed next to major depressive disorder also a high number 
of anxiety disorders (31.6%) and a comorbid personality disorders (49.4%). The sample size 
was smaller than anticipated and we missed follow-up assessment during pregnancy, but 
our generalized mixed models and sensitivity analysis confirmed our findings that there is 
no difference in reduction of depressive symptoms between the two treatment conditions. 
This might be related to the effect of our specialized TAU or the natural course of symptoms, 
leading to regression to the mean. However, the new GMT showed to be feasible, well-
accepted and a good option to reduce depressive symptoms during pregnancy. Depending on 
local availability and costs, clinicians should consider and discuss different treatment options, 
taking into account personal circumstances and preferences of the patient.  
Chapter 4 focuses on the impact of a mental disorder on sleep quality by comparing subjective 
and objective sleep quality in a case-control study. To measure objective parameters of sleep 
quality, all participants (21 cases and 33 healthy controls) wore a wrist actigraph for 7 days 
and nights. Subjective sleep quality was retrospectively assessed using the Pittsburgh Sleep 
Quality Index (PSQI) and on a daily basis with the Subjective Sleep Quality-scale (SSQ). 
Objective parameters of sleep quality and subjective sleep quality as assessed by the PSQI 
did not differ significantly between cases and controls. Daily sleep reports showed that, 
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S
relative to controls, cases had a significantly worse average SSQ-score. Our exploratory 
study suggests that perceived sleep quality reported on a daily basis by pregnant women with 
a mental disorder is worse than the sleep quality as measured by wrist actigraphy.
Chapter 5 explores patterns of mood fluctuations in pregnant women with a mental disorder 
by the weekly Profile of Mood state and investigates associations with obstetric outcomes and 
postpartum depression. We identified three patterns: highly variable, stable negative (more 
depressed/anxious) and stable positive mood. Our exploratory study showed that severe 
mood fluctuations might affect pregnancy outcomes. These findings need to be replicated in 
larger studies with repeated measurements. 
In Chapter 6, we describe the prevalence of suicidal ideation and self-harm events in pregnant 
women with schizophrenia related disorders and bipolar disorder, from a ‘new generation’ 
case register (CRIS) in London. Out of the 420 women in the study, 25% recorded suicidal 
ideation and 8% had a self-harm event during their pregnancy, with violent methods used in a 
fifth. Suicidal thoughts and self-harm occurred in a significant proportion of pregnant women 
with severe mental illness, particularly younger women and those with a history of self-harm; 
these women need particularly close monitoring for suicidality. We confirmed our hypotheses 
that self-harm was associated with illness severity, smoking, and previous self-harm, and 
though weaker evidence, non-affective diagnosis. 
Main findings of this thesis, methodological considerations, implications of current findings 
and recommendations for further research were discussed in Chapter 7. A limitation of our 
DAPPER-trial was the relatively small number of participants, which is a known problem in 
this hard to reach population. Next to participants with MDD, we included also a high number 
of participants with anxiety disorders and comorbid personality disorders. This heterogeneity 
reflects clinical practice and enhances generalizability of our studies. A specific characteristic 
of our study design was the patient-preference RCT and therefore its suitability for comparing 
the treatment effect of GMT vs. TAU, and additionally randomized vs. patient-preference 
conditions. A limitation of the measurements was that we did not investigate the course of 
anxiety symptoms thoroughly or other potential benefits of GMT above TAU (e.g. preparation 
of motherhood and enhancing social support). 
From our meta-analysis, as well from our RCT, we conclude that a form of psychotherapy 
(preferably CBT or IPT) needs to be offered to pregnant women with a mental disorder, but the 
different treatment options seem to be redeemable. However, we do need larger controlled 
trials to confirm this advice for non-pharmacological intervention for MDD, and also for the 
broader range of mental disorders. 
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samenvaTTing 
Het doel van dit proefschrift is om meer inzicht te krijgen in de behandeling en de impact van 
een psychiatrische stoornis tijdens de zwangerschap. 
Hoofdstuk 1 geeft een overzicht van de psychiatrische stoornissen die tijdens de 
zwangerschap voorkomen en stelt dat er een breder scala aan psychiatrische stoornissen 
en co-morbide stoornissen (zoals angst- en persoonlijkheidsstoornissen) prevalent is tijdens 
de zwangerschap. Het gaat om zwangeren, die eerder gediagnosticeerd zijn met een 
psychiatrische stoornis, of die voor het eerst psychiatrische symptomen ervaren tijdens de 
zwangerschap. Volgens de prevalentiecijfers, variërend van 3 tot 11%, lijkt een zwangerschap 
niet beschermend te zijn noch de uitlokkende factor te zijn voor psychiatrische klachten. De 
prevalentie, symptomen en specifieke zaken (zoals beloop en aandachtspunten) rondom een 
zwangerschap worden besproken voor depressieve stoornis, maar ook voor een bipolaire 
stoornis, angst gerelateerde stoornissen, eetstoornissen en schizofrenie en psychotisch 
gerelateerde stoornissen. Een psychiatrische stoornis tijdens de zwangerschap beïnvloedt 
de maternale stress in utero direct en wordt geassocieerd met een vertraagde foetale 
ontwikkeling, wat leidt tot een lager geboortegewicht en vroeggeboorte en een ongunstig 
effect heeft op de latere ontwikkeling van het kind. Naast de directe invloed van maternale 
stress, zijn er ook indirecte negatieve effecten van een psychiatrische stoornis, zoals een 
verminderde zelfzorg en toename van drugsmisbruik. Ook slaap- en stemmingsstoornissen 
worden vaak gerapporteerd tijdens de zwangerschap, maar er is weinig bekend over de 
specifieke patronen van stemming, en/of de kwaliteit van de slaap objectief slechter wordt of 
alleen de perceptie daarvan. 
De uitdaging in de behandeling van psychiatrische stoornissen tijdens de zwangerschap is 
het balanceren tussen de schadelijke effecten van de ziekte en de grotendeels onbekende 
effecten - op de foetus - van psychofarmaca. De NICE richtlijnen uit het Verenigd Koninkrijk 
adviseren om een  risico-baten analyse te doen, om het risico op een terugval af te wegen 
ten opzichte van het potentiële risico voor de foetus, en het gebruik van niet-farmacologische 
interventies aan te moedigen. Een nieuwe groepsdagbehandeling (GDB) met meerdere 
bestaande therapieën werd samengesteld uit andere evidence-based groepsbehandelingen 
voor stemmingsstoornissen. GDB is gericht om stress, depressieve en angstsymptomen te 
verminderen bij zwangere vrouwen, daarnaast is er een speciale focus op de emotionele 
en praktische voorbereiding van het moederschap. Deze wekelijkse open groepstherapie 
omvat cognitieve gedragstherapie (CGT), psycho-educatie, psychomotorische therapie en 
ontspanningstherapie. Een gerandomiseerde studie (de DAPPER-studie) evalueerde de 
groepsdagbehandeling en vergeleek het met individuele ambulante begeleiding (gouden 
standaard in Nederland) in de afname van depressieve symptomen bij zwangere vrouwen 
met een psychiatrische stoornis. Na een gestructureerd diagnostisch interview (SCID) 
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en schriftelijke toestemming, vulden de deelnemers drie vragenlijsten in over stemming 
en slaapkwaliteit tijdens de zwangerschap, met als primaire uitkomstmaat de Edinburg 
Depression Scale op 6 weken postpartum.
Hoofdstuk 2 is een samenvatting van de huidige literatuur over alle beschikbare behandelingen 
voor psychiatrische stoornissen bij zwangere vrouwen. Tot de dag van vandaag, zijn er geen 
gecontroleerde studies naar het effect van psychofarmaca voor psychiatrische stoornissen 
tijdens de zwangerschap. In onze meta-analyse konden we alleen de effectgrootte voor 
de behandeling van een depressieve stoornis schatten, door een gebrek aan studies over 
andere stoornissen. Een vorm van psychotherapie voor een depressieve stoornis heeft een 
robuust behandelingseffect, bijv. CGT (g=-0,61), en in mindere robuste mate, Interpersoonlijke 
Psychotherapie (IPT, g=-0,67). In deze analyse behouden beide behandelingen hun potentiële 
nut voor zwangere vrouwen met een depressieve stoornis. Dit is in lijn met de huidige NICE-
richtlijn die adviseert om een  vorm van psychotherapie aan te bieden aan elke zwangere vrouw 
met een milde tot ernstige depressie en benadrukt dat dit in nauw overleg met de patiënte 
moet gaan. Andere potentiële niet-farmacologische interventies voor de behandeling van een 
depressieve stoornis waren lichaamsgerichte interventies en acupunctuur. Lichttherapie was 
niet geassocieerd met een afname van depressieve symptomen, maar dit is gebaseerd op 
twee studies. Het behandeleffect van alle niet-farmacologische interventies lag dicht bij elkaar 
en behandelingen zijn dus mogelijk inwisselbaar voor elkaar, zeker rekening houdend met de 
hoge uitval. Daarom vinden wij dat de voorkeur van de patiënte zwaar mee mag wegen in de 
beslissing voor een psychiatrische behandeling in een klinische setting.
Hoofdstuk 3 beschrijft de DAPPER-studie, de eerste RCT van een klinische sample met 
zwangere vrouwen met co-morbide psychiatrische en psychosociale problemen. De 
DAPPER-studie evalueert een nieuwe groepsdagbehandeling (GDB) en is gericht op een 
afname van depressieve symptomen tijdens de zwangerschap. Samenvattend, er was geen 
significant verschil in de afname van depressieve symptomen tussen GDB en individuele 
begeleiding op 6 weken postpartum. We zijn wel succesvol geweest in het rekruteren 
van een moeilijk bereikbare populatie (n = 158); slechts 20 (11,2%) van de geschikte 
vrouwen weigerde studiedeelname, bijna twee op de drie deelneemsters heeft ingestemd 
met randomisatie en de drop-out was laag (9/155, 5,8%). We hebben naast de diagnose 
depressieve stoornis, ook een groot aantal angst gerelateerde stoornissen (31,6%) en co-
morbide persoonlijkheidsstoornissen (49,4%) vastgesteld. Het sample was klein en we misten 
een aantal follow-up metingen tijdens de zwangerschap, maar onze statistische analyses 
(mixed models) bevestigden onze bevindingen. Mogelijk vonden we geen verschil door het 
effect van onze gespecialiseerde individuele begeleiding en/of door het natuurlijk beloop. 
Echter, deze nieuwe groepsdagbehandeling is goed uitvoerbaar, geaccepteerd en zorgt voor 
een afname van depressieve symptomen tijdens de zwangerschap. Afhankelijk van de lokale 
beschikbaarheid en de kosten, zouden clinici de verschillende behandelingsmogelijkheden 
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moeten overwegen, rekening houdend met de persoonlijke omstandigheden en de voorkeuren 
van de patiënte.
Hoofdstuk 4 richt zich op de impact van een psychiatrische stoornis op de slaapkwaliteit door 
het vergelijken van subjectieve en objectieve slaapkwaliteit in een case-control studie. Van alle 
deelneemsters (21 patiënten en 33 gezonde controles) werden de objectieve slaapkwaliteit 
parameters gemeten door het dragen van een pols Actiwatch voor 7 dagen en nachten. 
Subjectieve slaapkwaliteit werd beoordeeld door de Pittsburgh Sleep Quality Index (PSQI) en 
op dagelijkse basis door een slaapdagboek met een Sleep Quality-schaal (SSQ). Objectieve 
slaapkwaliteit parameters en de uitslagen van de PSQI verschilden niet significant tussen de 
patiënten en gezonde controles. Uit de dagelijkse slaapdagboekjes bleek dat de patiënten, 
ten opzichte van de controles, een significant slechtere gemiddelde SSQ-score hadden. Onze 
verkennende studie suggereert dat de subjectieve slaapkwaliteit door zwangere vrouwen met 
een psychiatrische stoornis slechter is erger dan de objectieve slaapkwaliteit, gemeten door 
de Actiwatch.
In hoofdstuk 5 werden specifieke patronen van stemmingsschommelingen bij zwangere 
vrouwen met een psychiatrische stoornis onderzocht, door wekelijks de ‘Profile of Mood status’ 
te meten. Daarnaast werd het verband van deze patronen met verloskundige uitkomsten en 
postpartum depressie onderzocht. We identificeerden drie patronen: zeer variabel, stabiel 
negatief (meer depressief/angstig) en stabiel positieve stemming. Onze verkennende 
studie toonde aan dat een zeer variabele stemming zou kunnen resulteren in een lager 
geboortegewicht. Deze bevindingen moeten worden gerepliceerd in grotere studies.
In hoofdstuk 6 beschrijven we de prevalentie van suïcidale gedachten en automutilatie bij 
zwangere vrouwen met schizofrenie en psychotisch gerelateerde stoornissen of een bipolaire 
stoornis, door middel van een ‘nieuwe generatie’ case register (CRIS) in Londen. Van de 
420 vrouwen in het onderzoek hadden 25% suïcidale gedachten en 8% had geautomutileerd 
tijdens de zwangerschap, met gewelddadige methoden in een vijfde van de gevallen. Suïcidale 
gedachten en automutilatie traden op in een aanzienlijk deel van de zwangere vrouwen met 
een ernstige psychiatrische stoornis, met name bij jongere vrouwen en patiënten met een 
voorgeschiedenis van automutilatie. Deze patiënten moeten in het bijzonder nauwkeurig in de 
gaten worden gehouden om suïcidaliteit te beoordelen. We bevestigden onze hypothese dat 
automutilatie is geassocieerd met de ernst van de ziekte - roken, en eerdere automutilatie en 
daarnaast in mindere mate, een niet-affectieve diagnose. 
De belangrijkste bevindingen van dit proefschrift, de methodologische beschouwingen, 
implicaties van de huidige bevindingen en aanbevelingen voor verder onderzoek worden 
besproken in hoofdstuk 7. Een beperking van onze DAPPER-studie was het relatief klein 
aantal deelnemers, dit is een bekend probleem bij deze moeilijk te bereiken populatie. Naast 
de deelnemers met een depressieve stoornis, includeerden wij ook een groot aantal angst 
gerelateerde stoornissen en co-morbide persoonlijkheidsstoornissen. De heterogeniteit van 
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ons sample weerspiegelt de klinische praktijk en verbetert de generaliseerbaarheid van onze 
studies. Origineel was ook de studie-opzet, de patiënten-preferentie randomized controlled 
trial (RCT). Hiermee konden we het behandelingseffect van de groepsdagbehandeling 
vergelijken met de individuele begeleiding, en daarnaast konden we de vergelijking maken 
tussen de gerandomiseerde en de patiëntpreferentie conditie. Een beperking van de metingen 
was dat we niet grondig de algemene angstsymptomen hebben gemeten of andere potentiële 
voordelen van de groepsdagbehandeling, bijvoorbeeld een goede voorbereiding op het 
moederschap of een verbeterend steunsysteem. 
Vanuit onze meta-analyse, maar ook vanuit de bevindingen van onze RCT, concluderen wij 
dat een vorm van psychotherapie aangeboden dient te worden aan zwangere vrouwen met 
een psychiatrische stoornis en de verschillende behandelopties lijken inwisselbaar. Echter, 
we hebben grotere gecontroleerde studies nodig om deze stelling te bevestigen voor niet-
farmacologische interventies voor een depressieve stoornis, maar ook voor het bredere scala 
aan psychiatrische stoornissen. 
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Name PhD student: Leontien van Ravesteyn
Erasmus MC Department: Psychiatry & Obstetrics
Research School: NIHES
Promotor(s): Prof. Hoogendijk, Tiemeier & 
Steegers
Supervisor: Dr. M.P. Lambregtse - van den Berg
1. PhD training Year Workload 
(ECTS)
General courses 
- BROK (Basiscursus Regelgeving Klinisch Onderzoek)
- Basic Statistics Molmed, Erasmus MC
- Teach the Teacher-course, Desiderius School
- Integrity in medical research, Erasmus MC
- Biomedical English Writing and Communication, Erasmus MC
- Systematic literature retrieval in PubMed & Embase, Endnote
- Basic qualification in education (BKO), Desiderius School
18-3-2010
10-6-2010
13-2-2012
Apr 2012
Dec 2012
Feb 2013
Jun 2017
4.0
1.0
2.0
4.0
4.0
1.0
4.0
Specific courses (e.g. Research school, Medical Training)
- NIHES master ‘Clinical Epidemiology’
 Summer program 2011 & 2012 
 Core courses:
 Study Design
 Classical methods for data-analysis 
 Clinical Epidemiology 
 Methodological topics in epidemiologic research
 Modern statistical methods
 Advanced short courses:
 Courses for the quantitative researcher
 Repeated measurement in clinical studies
 Psychiatric epidemiology
 Child and maternal health
- SCID I and II training
- Research internship, King’s College London, supervisor prof. Howard
30-8-13
2012
2012
2012
2012
2012
2011
2013
2013
2013
2008
Sep’13-dec‘13
70.0
1.5 
22.0
Presentations
- Various presentations at the Department of Psychiatry of Erasmus MC
- Voorjaarscongres Nederlandse Vereniging voor Psychiatrie, “Dapper-
studie”, Amsterdam (oral presentation)
- Voorjaarscongres Nederlandse Vereniging voor Psychiatrie, “Zwanger 
en slaapproblemen”, Maastricht (poster presentation)
- LKPZ-symposium, “Alternatieve therapieën voor tocofobie”, Utrecht 
(workshop) 
- ISPOG society, “Objective and subjective sleep quality”, Berlin, 
Germany (poster presentation)
- EPA meeting, “Dapper-trial”, Ulm, Germany (oral presentation)
- Marce society, “Dapper-trial”, Swansea, UK (oral presentation)
2010 - 2014
31-3-2011
3-4-2012
20-9-2012
23-5-2013
23-4-2014
11-9-2014
3.0
1.5
0.6
1.5
0.6
1.5
1.5
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(Inter)national conferences
- Veilige Kribbe (Rotterdam)
- Voorjaarscongres NvvP (Maastricht)
- LKPZ-symposia  
- Marce society (Pittsburg, USA)
- Symposium “Neuro-imaging, genetics & endo, development & 
psychopathology” (Rotterdam)
- Symposium UKIMS (London, UK) 
- Symposium “Dwang&drang in de zwangerschap”(Rotterdam)
’09,’11,’13,‘15 
’10 - ‘14
’10, ’12, ‘15
28-10-2010
02-09-2010
19-9-2013
28-1-2016
1.2
1.5
1.0
0.5
0.3
0.3
0.5
Seminars and workshops
- PhD-day
- CPO-symposium
- BKO-workshop: “Individuele begeleiding”
- NICE-guidelines “Perinatal psychiatry” seminar, London
- Global mental health course, London School of Hygiene & Tropical 
Medicine
- BKO-workshop: “Tentamenvragen maken” 
- BKO-workshop: “Omgaan met groepen”
- Loopbaanorientation, Desiderius School
- Medical Business Masterclasses
Mar 2010
Feb 2010
Jun 2013
Nov 2013
Nov 2013
Dec 2013
Dec 2013
Mar 2014
Apr 2014
0.3
0.3
0.1
0.3
0.5
0.1
0.1
1.5
1.5
2. Teaching Year Workload 
(ECTS)
Supervising practicals and excursions, tutoring
- Vaardigheidsonderwijs ‘De tuchtzaak’
- 2nd year ‘keuzeonderwijs’ medical students 
- Vaardigheidsonderwijs ‘Het kraambed’
- Minor ‘Womens health: from fetal life to ageing disease’
- Begeleider Kennismaking Beroepspraktijk medical students
2009 - 2012
2010 - 2014
2012
2011
2012
1.5
4.0
0.5
0.5
1.0
Supervising Master thesis Erasmus MC
- Laura Schot
- Silvia Koeleman
- Esther Mooij
- Yvette Konijnendijk
- Monique Roggeveen
- Kim Schuurbiers
2010
2012
2012
2012
2012
2013
18.0 
Other
- Therapist group-based multicomponent therapy (psycho-education) 
- Onderwijs & Onderzoek feestcommissie
- Initiator Research meeting Womens Mental Health
- Organisation of Veilige Kribbe-conference 2013 
2010 - 2014 
2010 - 2013
2012 - 2014
Jul - dec ’13
4.0
0.5
1.0
2.0
Note: 1 ECTS (European Credit Transfer system) equals a workload of 28 hours
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dankwoord
Een interessant, leerzaam en uitdagend traject stond aan de basis van het resultaat dat u nu in 
uw handen heeft. Er zijn veel personen die ik wil bedanken voor hun bijdrage, betrokkenheid 
en interesse aan de totstandkoming van dit proefschrift. Tijdens mijn promotietraject ben ik 
begeleid door een inspirerend en gemêleerd team van wetenschappers die elk een andere 
rol op zich namen. 
De DAPPERe patiënten verdienen als eerste mijn dank. Ik ben deze vrouwen zeer erkentelijk 
voor hun waardevolle bijdrage aan de studies. Zij hebben mij een leerzame indruk gegeven 
van het leven van een Rotterdamse zwangere. Door hun openheid, zowel in de kliniek als 
bij hen thuis, ben ik getuige geweest van vele prachtige momenten, maar ook van hun 
teleurstellingen.
Veel dank gaat uit naar mijn copromotor dr. Lambregtse – van den Berg. Beste Mijke, 
bedankt voor het vertrouwen om dit traject aan te gaan met zo’n jonge studente en voor de 
mogelijkheid om dit te combineren met coschappen, een master en tropenopleiding. Ik vind 
het heel knap hoe jij alles combineert en jezelf blijft uitdagen om het tot een hoger klinisch en 
wetenschappelijk niveau te brengen. Ik weet zeker dat door jouw harde werken er nog veel 
mooie projecten tot bloei komen!
Ik wil graag mijn drie promotoren bedanken, die als een goed functionerende drie-eenheid 
werkten: prof. dr. Hoogendijk, prof. dr. Steegers en prof. dr. Tiemeier. Beste Witte, bedankt 
voor het inzicht, de opbouwende feedback en de mogelijkheden die u mij heeft gegeven. 
Beste Eric, ik wil u bedanken voor de betrokkenheid bij dit project. Opnieuw bleek dat de 
samenwerking van de afdeling Verloskunde & gynaecologie en de Psychiatrie erg belangrijk 
is, zowel op klinisch als op wetenschappelijk gebied! Beste Henning, bedankt voor het kritisch 
beoordelen van de manuscripten en de interessante discussies. 
Geachte leden van de beoordelingscommissie, veel dank voor de moeite die u heeft genomen 
bij het beoordelen van dit proefschrift. 
Monique Raats en Tom Schneider, hartelijk bedankt voor jullie hulp en betrokkenheid tijdens 
en na de DAPPER-studie – één van de vele vruchten van jullie gezamenlijke inspanningen. 
Ik wil jullie bedanken voor de interessante gesprekken en uitjes die mij in de volle breedte 
hebben ontwikkeld. Van Facet (beraadsgroep over gedwongen anticonceptie) tot de 
achterstandswijken in Berlijn, van Rotterdamse studenten uitdagen in ethische discussies tot 
de politiek in Den Haag, van het organiseren van de dagbehandeling in het EMC tot aan de 
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Veilige Kribbe in Diergaarde Blijdorp! Elke keer vonden we elkaar in de verantwoordelijkheid 
die we voelen voor de rechten en plichten van (zwangere) vrouwen met psychische klachten 
en haar (ongeboren) kind in de grote stad. Ik hoop snel weer eens bij te praten!
Ik wil graag de afdeling Psychiatrie bedanken. In het bijzonder Astrid Kamperman, zonder jou 
was ‘het boekje’ niet afgekomen. Heel erg bedankt voor je betrokkenheid, statistische bijstand 
en enthousiasme. Je bent erg waardevol voor elke (psychiatrische) promovendus! Bedankt 
Joke Tulen en Wai Chow voor de zichtbare en onzichtbare hulp en ondersteuning. 
Veel dank aan mijn collega-onderzoekers en arts-assistenten van de afdeling Psychiatrie voor 
jullie medewerking en gezelligheid. Jeroen Vervoort, dank voor al je hulp bij de DAPPER-
studie en al je praktische tips over zwangere vrouwen. Erwin Birnie, bedankt voor de 
methodologische kant van de DAPPER-studie. Ik wil mijn keuze-onderzoeksstudenten (Laura, 
Esther, Monique, Silvia, Kim en Yvette) hartelijk bedanken voor jullie inzet en enthousiasme 
voor de perinatale psychiatrie. Het gaf mij veel plezier om met jullie te werken. 
Dear prof. Howard, thank you for collaborating and your hospitality in London. Your in-dept 
knowledge, tremendous work ethic and commitment is extraordinary. Thanks Clare Taylor, for 
the ‘gezelligheid’ and successful collaboration on the self-harm paper. You’re always welcome 
again in Amsterdam.  
Ik wil graag mijn collega’s en opleiders bedanken voor hun steun en betrokkenheid tijdens 
mijn (tropen)opleiding. Bedankt dr. Den Boer (Zaans MC) dat u iemand met een ‘psychiatrisch’ 
profiel aannam bij de chirurgie. Ik wil de maatschap chirurgie van het Slingeland ziekenhuis, 
en in het bijzonder dr. Staal en dr. Lemson, heel erg bedanken voor de leerzame en leuke 
tijd in Doetinchem en in Sengerema. Fantastisch om te zien hoe jullie het met elkaar en de 
tropenopleiding hebben georganiseerd. Hopelijk komen we elkaar weer tegen in de toekomst. 
Dr. Paarlberg, bedankt voor de fijne tijd in het Gelre ziekenhuis en de inzichten van de 
uitstekende Apeldoornse POP-poli. 
Ik dank mijn lieve vrienden en vriendinnen. Weet dat ik jullie erg waardeer! 
Lieve Luna’s, het is alweer 12 jaar geleden dat we elkaar leerden kennen. Het is heel mooi om 
te zien hoe we elkaar elke keer weer vinden in de verschillende fases.  
Lieve Ladies, ik ben nog steeds heel trots op ons mooie dispuutje, waar iedereen heerlijk 
zichzelf kan zijn. Laten we alsjeblieft de mooie tradities in ere houden, ik kijk er naar uit! Cath, 
heel knap om te zien hoe jij elke keer weer het uiterste uit je zelf. Houd moed bij jouw PhD 
avontuur! Momo, als eerste een kindje gekregen en als eerste specialist! Wauw! Maso’ulat, 
snel weer eens op pad? 
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Bedankt gezellige cogroep, IFMSA- en studievrienden voor alle interesse en afleiding! En nu 
is het einde van de tropenopleiding nabij. Bedankt leuke tropenvrienden en in het bijzonder, 
de NTC-groep en TROIE. Ik voel mij bij jullie als een vis in het water.
Lieve Mathilde, mijn paranimf. Ik vind het heel leuk dat je vandaag aan mijn zijde staat. Meestal 
lopen we met de honden, maar weet dat ik jouw interesse en meningen erg waardeer! Ik kijk 
uit naar onze toekomstige uitstapjes!
Karin, mijn lieve paranimf! Wat ben ik blij dat wij elkaar ontmoet hebben en samen de 
verschillende (promotie-) trajecten hebben doorlopen. Ik vind het heel knap hoe je alle 
balletjes in de lucht hebt gehouden afgelopen jaar. Gelukkig vindt nu alle gezelligheid buiten 
het EMC plaats, en volgen er nog veel mooie dingen!
Familie, de voor jullie vanzelfsprekende warmte die ik ervaar, is voor mij de grootste rijkdom. 
Lieve papa en mama, ongelofelijk hoeveel liefde en energie jullie in jullie (klein) kinderen 
stoppen. Ik houd van jullie. En natuurlijk samen met Dymphna en Arnoud, heel lief hoe 
jullie naar m’n verhaaltjes luisteren en altijd voor mij zorgen. En niet te vergeten, mijn oud-
huisgenoten Cees & Alice, heel erg bedankt voor de warme gastvrijheid en betrokkenheid! 
Lieve Joris, wat heb ik het fijn met jou! Jij moedigt mij altijd aan om dingen te doen die ik 
echt leuk vind en geeft mij daar alle vrijheid in. We vullen elkaar goed aan en ben blij dat je 
mee bent gegaan op ons tropische avontuur. Ik kijk erg uit naar de toekomst met jou (zonder 
beeldschermen). Ik houd van jou!
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